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Pancreatic cancer has the highest mortality rate of all major cancers with a 
5-year survival rate of 8%. A major contributor to this statistic is the lean muscle 
loss that occurs with cachexia, a condition found in 80% of pancreatic cancer 
patients. The effects of two potential cachexia treatments—the branched-chain 
amino acid, leucine, and its metabolite, β-hydroxy-β-methylbutyrate (HMB)—have 
been analyzed in multiple studies. However, most of these studies have 
determined their effects on muscle tissue only, while their effects on pancreatic 
tumor growth remain unknown. The objective of this current study was to 
evaluate the impact of dietary leucine and HMB supplementation on pancreatic 
ductal adenocarcinoma (PDAC) in pro-tumor and anti-tumor environments and 
identify potential mechanisms of inhibition or enhancement.  
Using C57BL/6 male mice, we demonstrated that dietary leucine 
supplementation enhanced pancreatic tumor growth in both the pro-tumor 
environment of overweight mice and the anti-tumor environment of lean mice. 
vi  
Leucine supplementation increased the amount of circulating glucose available 
for the tumor in the overweight mice, while it increased tumor mechanistic target 
of rapamycin (mTOR) activation in the lean mice.  
Next, we determined that dietary HMB supplementation preserved muscle 
mass through increased muscle mTOR activation. HMB supplementation also 
inhibited pancreatic tumor growth and enhanced the efficacy of the chemotherapy 
gemcitabine in the pro-tumor environment of obese C57BL/6 mice. HMB 
supplementation downregulated numerous olfactory receptor genes that were 
upregulated in the tumors of obese mice, and HMB also increased cytotoxic 
CD8+ T cell infiltration in these tumors.  
Additional experiments were conducted to determine the potential 
mechanisms for the effects of leucine and HMB on pancreatic cancer. We 
showed leucine supplementation increased, while HMB supplementation 
decreased, both human and murine pancreatic cancer cell proliferation and 
mTOR signaling. Leucine and HMB also had differential effects on the regulation 
of certain olfactory receptor genes, and octanal, an olfactory receptor agonist, 
could mimic the repressive effects of HMB supplementation on pancreatic cancer 
cell proliferation.  
Collectively, these findings suggest that HMB has the most potential for 
cancer cachexia treatment due to its ability to preserve muscle mass, reduce 
tumor growth, and enhance the effects of chemotherapy. The in vivo results 
suggest leucine and HMB can affect tumor indirectly by manipulating physiology, 
and the in vitro findings suggest they can also affect cancer cells directly.  
vii  
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Obesity, Cachexia and Cancer  
 
The prevalence of obesity, defined as a body mass index (BMI) of ≥ 30 kg/m2, 
has remained high in the United States (US) for decades with 1 in 3 adults and almost 
1 in 5 children obese (1). Obesity is a well-established risk and progression factor for 
many cancers (including pancreatic cancer) and contributes to 15-30% of cancer 
deaths in the US (2).  
While obesity can enhance tumor growth, another condition called cancer 
cachexia, can weaken the patient. Cachexia, which is characterized by significant 
muscle loss, is estimated to be the cause of death in 20% to 40% of cancer patients 
and is present at the highest incidence in gastric, pancreatic, and lung cancer patients 
(3). The combination of obesity and cachexia results in the poorest prognosis due to 
simultaneous enhancement of tumor progression and metabolic and immune 
dysregulation that weaken the body and increase mortality risk (4).  
Due to the obesity epidemic in Western society, a growing proportion of 
pancreatic cancer patients at the start of therapy have a body mass index (BMI) in the 
overweight or obese range. Many of these individuals have sarcopenic obesity, a 
condition characterized by the presence of high fat mass but low muscle mass 
(sarcopenia). Recent studies have reported that obesity in the presence of sarcopenia 
is predictive of morbidity and mortality in pancreatic cancer patients, at least in part 
because sarcopenic obesity increases the odds of developing cancer cachexia (5). 
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Given the consistently high prevalence of obesity and no approved medications to treat 
cachexia and muscle loss in cancer patients, mortality rates will continue to be high in 
these patients (3). Therefore, it is crucial for research to be performed that aims to 
identify potential treatments for cachectic muscle loss that are safe to administer to 
cancer patients. 
 
Diet and Changing the Physiological Environment 
 Obesity is associated with cancer growth because of its ability to alter the body’s 
physiological environment. Obesity is associated with increased growth signaling and 
increased systemic inflammation in humans, and the diet-induced obesity (DIO) 
regimen induces a similar pro-tumor environment in animal models (2,6). This 
translates to DIO-induced enhancement of tumor growth in these animal models (7-9). 
The DIO regimen is a diet with 60% total calories from fat and is usually compared to a 
control diet with only 10% total calories from fat (7).  
In contrast, calorie restriction (CR) acts as a potent inhibitor of cancer growth in 
animal models by creating an anti-tumor environment and inhibiting the same growth 
and inflammatory pathways enhanced by DIO (10). The CR regimen restricts total 
calorie intake by 30% relative to ad libitum-fed controls, while maintaining isonutrient 
conditions to avoid malnutrition (11).  
The pro- and anti-tumor effects of the DIO and CR diets are consistent across 
species, tumor type, and method of tumor induction, suggesting that systemic 
circulating factors may be mediators of the growth and inflammatory pathways 
important to cancer growth (10-11). In addition, these pathways are also relevant when 
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studying potential cachexia treatments, because most cachexia research has focused 
on how aberrations in growth signaling and inflammation affect muscle growth and 
breakdown (12). Due to the importance of these pathways for both tumor growth and 
muscle preservation, the next section will discuss them in detail.  
 
Mechanisms Associated with Diet Effects on Tumor and Muscle 
 The obesigenic DIO diet creates a pro-tumor environment associated with high 
levels of multiple circulating factors that enhance either growth signaling or 
inflammatory pathways within tissues. Insulin and insulin-like growth factor-1 (IGF-1), 
and adiponectin affect growth signaling, while the hormone leptin and pro-inflammatory 
cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), IL-6, 
IL-17A affect inflammatory signaling.  
 Defining the factors that modulate growth signaling, insulin is a peptide hormone 
synthesized by pancreatic β-cells in response to elevated blood glucose (13). IGF-1 is 
a peptide growth factor produced by the liver and is responsible for facilitating growth 
and development of many tissues (14). Adiponectin is a hormone secreted by 
adipocytes involved in regulating glucose and fatty acid breakdown, and it is often seen 
as an antagonist to leptin (15). While these hormones have different functions, their 
effects on cancer can be largely attributed to their actions on one pathway involving the 
mechanistic target of rapamycin (mTOR).  
Circulating insulin and IGF-1, which are positively associated with adiposity, 
attach to their respective receptors on the cell surface, and activation of these receptor 
tyrosine kinases stimulates PI3K to produce lipid messengers. They activate Akt, which 
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then leads to the phosphorylation and activation of mTOR and downstream regulator of 
protein translation, ribosomal S6 kinase 1 (S6K1) (15-16). This mTOR-induced 
increase in global protein translation is associated with increased tumor growth (18), 
and inhibition of the mTOR pathway inhibits cancer growth in various in vivo and in vitro 
models (19-22). On the other hand, adiponectin, which is negatively-correlated with 
adiposity, reduces mTOR signaling through activation of AMP-activated kinase (AMPK) 
(13). AMPK inhibits mTOR by phosphorylation of the tuberous sclerosis complex 2 
(TSC2). This stabilizes the TSC1-TSC2 complex and allows it to inhibit Ras homolog 
enriched in brain (Rheb), which is then unable to activate mTOR (23). Adiponectin can 
also inhibit inflammatory pathways by inhibiting nuclear factor κ light-chain enhancer of 
B cells (NF-κB), which is discussed below (24). 
 Defining the factors that modulate inflammatory pathways, leptin is a peptide 
hormone produced by adipocytes and primarily functions as an energy sensor (25). 
TNF-α is produced largely by macrophages and is involved in the regulation of immune 
cells (26). IL-1β is produced by macrophages and undergoes further processing to 
become active in mediating the inflammatory response (27). IL-6 is secreted by T cells 
and macrophages to stimulate the immune response (28). IL-17A is produced by T-
helper cells and helps in the recruitment of monocytes and neutrophils to sites of 
inflammation (29). Although the original functions for leptin and pro-inflammatory 
cytokines are different, their effects on cancer are largely due to their effects on 
transcription factors. 
Leptin binds to its receptor, which is similar to a class I cytokine receptor (13), 
and activates Janus kinases (JAKs). These kinases phosphorylate each other and 
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intracellular end of their receptors in order to create docking sites for signal transducers 
and activators of transcription (STATs). JAK-induced phosphorylation of STATs 
activate them, and they translocate to the nucleus and bind to DNA (30). The STAT 
transcription factors then enhance transcription of various genes involved in cell 
growth, proliferation, and survival. Due to the wide array of genes it regulates, STAT 
dysregulation is often associated with cancer (31). STAT activation is also tied to 
inflammation through a few inflammatory cytokines (IL-6, IFN-γ, IL-10) (30). However, 
the most well-studied and prominent of inflammatory pathways is the canonical NF-κB 
pathway.  
NF-κB is normally attached to inhibitor of κB (IκB) proteins in the cytoplasm of 
cells. When cells are exposed to pro-inflammatory cytokines, the IκB kinase (IKK) 
complex activates and phosphorylates the IκB proteins. This targets the IκB proteins for 
ubiquitin-dependent breakdown and frees NF-κB, which translocates to the nucleus 
and enhances the transcription of multiple genes (32). Many of these genes code for 
proteins involved in immunity, proliferation, and the inhibition of apoptosis. Through 
transcription of these genes, NF-κB activation promotes tumor growth, while NF-κB 
inhibition reduces tumor growth in various cancer models (32-38) in vivo and in vitro 
cancer models.  
Although there are numerous pathways that affect tumor growth and often cross-
talk between these pathways, mTOR and NF-κB are specifically highlighted, because 
they have significant roles in skeletal muscle as well. There is extensive literature 
supporting the role of the mTOR pathway in regulating skeletal muscle hypertrophy by 
increasing protein translation and synthesis (39-40). mTOR signaling promotes muscle 
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growth regardless of animal model or type of muscle atrophy studied, including disuse 
(41), denervation (42), disease-induced (43). When mTOR activation is inhibited, 
muscle wasting occurs (44). 
NF-κB signaling, on the other hand, promotes muscle atrophy. In muscle, NF-κB 
specifically enhances the transcription of muscle RING finger 1 (MuRF-1), which is an 
atrogene. MuRF-1 is a ubiquitin ligase, involved in the rate-limiting step of the 
ubiquitination process of the ubiquitin-proteasome system. This makes it a crucial 
enzyme for proteasome-dependent degradation of proteins, so it is upregulated during 
muscle breakdown (45). Mice lacking MuRF-1 are resistant to muscle atrophy induced 
by denervation (46) or dexamethasone (47), and if NF-κB is inhibited, muscle atrophy 
induced by denervation (48) or hindlimb unloading (49) is inhibited. 
In summary, mTOR signaling promotes tumor and muscle growth, while 
inflammatory NF-κB signaling promotes tumor growth and muscle breakdown. Due to 
the significance and tissue specificity of mTOR and NF-κB action, potential treatments 
for cancer cachexia should be evaluated for their effects on these pathways. 
 
Nutritional Supplementation to Preserve Muscle Mass 
 There is considerable support in the literature for using nutritional 
supplementation to improve cachectic symptoms in cancer patients, and while a 
number of nutritional regimens have been suggested, much of the research focuses on 
supplements that improve muscle growth or inhibit muscle breakdown (50-51). This 
focus on muscle has led researchers to study amino acids, the building blocks of 
protein, and ascertain whether they have effects on growth and inhibition signaling as 
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well. The goal is to discover a supplement that can be not only an activator of growth or 
inhibitor of breakdown, but also utilized itself for protein synthesis.  
The branched-chain amino acids, leucine, isoleucine, and valine, are found at 
high percentages in skeletal muscle, and can increase human muscle protein synthesis 
almost to the same extent as complete meals (52). Leucine alone stimulates human 
muscle protein synthesis, although for a shorter duration (52). It is also the leucine 
content of dietary proteins that is the determining factor for muscle protein synthesis in 
rats (53). This is because, leucine activates mTOR within skeletal muscle (54). Thus, 
leucine supplementation is a popular potential treatment for cachexia.  
Due to rising interest in leucine, research began to be conducted on its 
metabolites. One in particular, β-hydroxy-β-methylbutyrate (HMB), increases muscle 
mTOR activation and muscle growth (55-56).  HMB also inhibits muscle NF-κB 
activation and inhibits muscle atrophy (56-57). Thus, HMB supplementation, which is 
actually better tolerated than leucine (58), is another popular potential treatment for 
cachexia. However, due to the focus of cachexia research on muscle, not much is 
known about how these supplements affect tumor growth. If these supplements are 
going to be administered to cancer patients with cachexia, examining their effects on 
tumor growth is important.  
 
Analyzing Pancreatic Cancer Growth In Vivo and In Vitro 
 To determine the effects of leucine and HMB on tumor growth, the type of 
cancer, animal model, and method of tumor induction needed to be selected. Pancreatic 
cancer, C57BL/6 male mice, and Panc02 cell subcutaneous injection were chosen 
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based on the following reasons: 1) Cachexia occurs in 80% of pancreatic cancer 
patients (59). 2) Diet, both obesigenic and calorie restrictive, affect pancreatic tumor 
growth (60-61). 3) Pancreatic cancer is dependent on both the mTOR and NF-κB 
pathways for growth (60-61). 4) C57BL/6 mice are well-known to respond physically to 
different diets and have been successfully used to study pancreatic cancer (60-61). 5) 
Male C57BL/6 mice do not have an estrous cycle, which can affect growth hormone 
levels and indirectly affect pancreatic tumor growth (62). 6) Panc02 cells are syngeneic 
to the C57BL/6 mice (60). 7) Subcutaneous tumors are easily palpated, monitored, 
excised, and measured ex vivo (60-61). 8) There are no studies of leucine or HMB 
supplementation in a pancreatic tumor model.  
 Pancreatic cancer cells were used to further confirm effects found in the animal 
studies. Two murine (Panc02 and NB508) and two human (Panc-1 and MiaPaca-2) 
pancreatic cancer cell lines were used. The Panc02 line was originally derived from a 
chemically-induced PDAC in the pancreas of C57BL/6 mice (63). The NB508 line was 
originally derived from the Kras/INK4A transgenic mouse, which has a mutant K-ras and 
a heterozygous deletion for INK4A. These genes are the most commonly mutated in 
spontaneous human PDAC (64). The Panc-1 and MiaPaca-2 cell lines were originally 
derived from different human PDACs (65-66). The data presented in Chapters II, III, and 
IV demonstrate the effects of leucine and HMB supplementation on in vivo and in vitro 






Potential Interplay Between Diet and Cytotoxic T Cells 
 While understanding how diet and supplementation affect tumor growth is 
important, understanding how they affect the physiological environment can be vital 
when interpreting results. High levels of inflammatory markers are often associated with 
obesity, and this chronic inflammation can affect immunologic cells, including dendritic, 
natural killer, and T cells (67). Cytotoxic CD8+ T cells are associated with reduced 
pancreatic tumor growth and a more positive prognosis if they infiltrate the tumor (68). 
Unfortunately, the pro-tumor obese environment is associated with decreased cytotoxic 
CD8+ T cell levels (67,69). This may be due, in part, to dysregulated NF-kB signaling, 
which impacts T cell differentiation. NF-kB activity is important for CD8+ T cell synthesis 
specifically, because the inhibition of NF-kB activity results in lower numbers of CD8+ T 
cells both in the thymus and in circulation (70). TNF-α inhibition results in the same 
reduction of CD8+ T cell-mediated activity (71).  
Although the aforementioned effects seem contradictory to the obesity-induced 
low T cell numbers, negative feedback loops can be activated during chronic 
inflammation. IL-2, a promoter of T cell synthesis, upregulates the transcription of its 
own inhibitor, FOXP3 (72). NF-kB itself also enhances the transcription of its own 
repressor (IκBα) (73). HMB supplementation has been shown to inhibit inflammatory 
and NF-kB signaling in various tissues, so it may also play a role in cytotoxic T cell 
regulation as well. Whether HMB supplementation can affect the immune system is 





Potential Interplay Between Diet and Olfactory Receptors 
 Identifying how diet and supplementation may change pancreatic cancer cells is 
also important to understand the entire story. The pro-tumor, obese environment can 
also affect gene regulation in tissues, specifically cancer-related genes and olfactory 
receptor genes. Mice on a high-fat diet had upregulation of olfactory receptors and 
cancer-related genes in subcutaneous fat tissue and gastrocnemius muscle compared 
to mice on a non-fat diet (74). The upregulation of cancer-related genes makes sense, 
because it is well-known that obesity enhances tumor growth (13). However, the reason 
for obesity-induced upregulation of olfactory receptor genes is unknown.  
The olfactory receptor gene family is the largest in the mammalian genome, and 
olfactory receptor expression can be detected in non-olfactory tissues (75). Thus, it is 
reasonable to assume they may play non-olfactory roles. In fact, cancer cells may be 
utilizing them for their own purpose, as olfactory receptor expression is highly 
dysregulated in various cancer cells, including prostate and pancreatic (76-77). This 
data is correlative, however, and no mechanistic conclusion can be attained through the 
literature. Chapter IV will explore the effects of HMB and leucine on olfactory receptor 













The overall goal of this project was to determine the impact of leucine and HMB 
supplementation, two potential cancer cachexia treatments, on pancreatic tumor growth 
in a mouse model and to elucidate potential mechanisms underlying these effects. 
Different diets were included to provide either anti-tumor or pro-tumor environments, 
because these nutritional supplements may be provided to patients with different diet-
induced physiological environments. The individual specific aims were as follows: 
 
1) Characterize the effects of dietary leucine supplementation on pancreatic tumor 
growth in lean (CR) and overweight (control) mice (Chapter II). We evaluated diet- 
and leucine-induced changes on physiological parameters (body weight, lean mass, fat 
percentage, serum hormones, glucose tolerance), and on pancreatic tumor growth in 
C57BL/6 mice. Immunohistochemistry was performed to determine the effects of CR and 
leucine on tumor cell proliferation (Ki-67) and mTOR activation (p-S6). MTT assays and 
western blot analyses were performed to determine the effects of CR and leucine on 
Panc02 cell proliferation and mTOR activation. 
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2) Characterize the effects of dietary HMB supplementation on pancreatic 
tumor growth and muscle breakdown in overweight (control) and obese 
(DIO) mice treated with gemcitabine (Chapter III). We evaluated diet- and 
HMB-induced changes on physiological parameters (body weight, serum 
hormones, serum cytokines, muscle size) and on pancreatic tumor growth in 
C57BL/6 mice. Immunohistochemistry was performed to determine the effects of 
DIO, gemcitabine, and HMB on tumor cell proliferation (Ki-67) and mTOR 
activation (p-S6). A microarray was performed to determine the effects of DIO 
and HMB on tumor gene expression, and immunohistochemistry and qPCR were 
done to validate and further explore the results.  
 
3) Determine the mechanisms by which leucine and HMB supplementation 
affect murine and human pancreatic cancer cells (Chapter IV). We 
evaluated leucine- and HMB-induced changes in murine (Panc02 and NB508) 
and human (Panc-1 and MiaPaca-2) cells. MTT assays and western blot 
analyses were performed to determine the effects of supplementation on 
pancreatic cancer cell proliferation and mTOR signaling, respectively. Seahorse 
experiments were performed to determine effects on cellular metabolism, and a 
microarray was done to determine effects on gene expression. As a follow up to 
the microarray results, MTT assays with olfactory receptor agonists and qPCR 









Leucine supplementation differentially enhances pancreatic 
cancer growth in lean and overweight mice (78)1. 
 
Introduction 
Effective prevention and treatment strategies are urgently needed for 
pancreatic cancer, the 4th leading cause of cancer-related death in both men and 
women in the United States (79). Less than 15% of pancreatic cancer patients have 
localized disease amenable to curative resection, and the overall 5-year survival 
rate in affected patients is less than 5% (80). Obesity is an established pancreatic 
cancer risk and progression factor in humans and animal models (81-83). In 
contrast, calorie restriction (CR) prevents or reverses obesity and related metabolic 
perturbations and pancreatic tumor development and/or progression in 
experimental models (84-85,87-89); the impact of CR on human pancreatic cancer 
has not been well studied. CR results in a negative energy balance state and exerts 
its antitumor effects, at least in part, through decreased mammalian target of 
rapamycin (mTOR) signaling in many epithelial tissues (84, 85-88). mTOR acts as 
a nutrient sensor that regulates protein synthesis, cell survival, and proliferation in 
response to growth factor levels, nutrient availability, and intracellular energy 
status. We have previously established that rapamycin (a selective mTOR 
                                                          
1 Liu KA, Lashinger LM, Rasmussen AJ, Hursting SD. Leucine supplementation differentially enhances 
pancreatic cancer growth in lean and overweight mice. Cancer Metab. 2014;2:6. Lashinger contributed to 
ideas, animal study, and editing. Rasmussen contributed to animal study. Hursting contributed to ideas, 
finances, writing, and editing. 
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inhibitor), and metformin (an indirect inhibitor of mTOR signaling through its effects 
on gluconeogenesis and associated activation of AMPK-regulated signals), partially 
mimic the tumor inhibitory effects of CR on transplanted pancreatic tumor growth 
(89). 
Branched-chain amino acids (BCAAs), which account for over 20% of total 
dietary protein intake, are known activators of the mTOR pathway in muscle and 
epithelial tissues (90-92). Of the three BCAAs, leucine exerts the most potent effect 
on mTOR activation and enhancement of protein synthesis in various tissues, 
including skeletal muscle (93-94). Athletes commonly use leucine supplementation 
to activate mTOR-regulated protein synthesis and accelerate muscle repair and 
regeneration after injuries or intense bouts of exercise (95). Leucine 
supplementation is also increasingly being recommended to reduce the muscle 
wasting that occurs with cancer cachexia (95). Cachexia is characterized by 
involuntary weight loss and muscle wasting, is associated with increased morbidity 
and mortality, and frequently occurs in pancreatic cancer patients (97). Increased 
muscle protein synthesis in response to leucine-induced mTOR activation has been 
shown to inhibit muscle wasting in mouse models of cancer cachexia and in cancer 
patients (98-101). However, the rates of protein synthesis increase to a much 
greater extent in tumors than in muscle (100), suggesting that while leucine 
supplementation may protect against cancer-associated cachexia, it may also 
enhance the progression of the cancer. 
Unfortunately, studies of the effects of leucine supplementation on cancer 
are limited. Long-term leucine supplementation (2% of diet, w/w) promoted bladder 
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cancer development in rats treated with a known bladder carcinogen (102-103), but 
no studies have connected leucine supplementation with tumor growth. In the 
present study, we tested the effect of leucine supplementation on transplanted 
Panc02 mouse pancreatic cancer growth and mTOR signaling in the context of 
lean mice (fed a CR diet regimen) or overweight mice (fed a high calorie control 
diet regimen). Our findings suggest that leucine enhances pancreatic tumor 
progression in lean and overweight mice, and the underlying mechanisms may 




























Materials and Methods 
Mice and dietary interventions 
All experiments were conducted under a protocol approved by the 
Institutional Animal Care and Use Committee at the University of Texas at Austin. 
Eighty-eight male C57BL/6 mice were obtained from Charles River Breeding 
Laboratories (Wilmington, MA, USA) at 6 to 8 weeks of age, and upon arrival were 
singly-housed in a semibarrier facility at the University of Texas at Austin Animal 
Resource Center and fed a chow diet during a one-week acclimation period. Mice 
were then randomized to receive one of four diets for 27 weeks: (i) AIN-76A control 
diet consumed ad libitum (control, n = 22); (ii) 30% CR diet (CR, n = 22); (iii) control 
diet with leucine supplementation (5% of diet, w/w) consumed ad 
libitum (control + LEU, n = 22); or (iv) 30% CR diet with leucine supplementation 
(CR + LEU, n = 22). The AIN-76A control diet, when consumed ad libitum, results in 
an overweight phenotype characterized by steady weight gain, while the CR results 
in a lean phenotype characterized by weight maintenance (104-105). Both CR diets 
were administered as a daily aliquot providing 70% of the total energy but 100% of 
the vitamins, minerals, amino acids and fatty acids consumed by the controls. 
Leucine was purchased from AIDP, Inc. (City of Industry, CA, USA) and was 
incorporated into the AIN-76A diet premix to provide 50 g/kg feed, or 5% dietary 
leucine supplementation. This dose of leucine is commonly used in animal studies 
of muscle regeneration (106-107). All diets were purchased from Research Diets 
(New Brunswick, NJ, USA). 
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Energy intakes and body weights for each mouse were recorded weekly 
for 21 weeks, and then glucose tolerance tests (GTTs) were performed on a 
randomly selected subset of animals (n = 10/group). After injecting a 20% (w/v) 
glucose solution, blood glucose levels were measured with a Contour glucometer 
(Bayer HealthCare LLC, Mishawaka, IN, USA) at baseline, 15, 30, 60, and 120 
minutes. Also after the rats were on the diet for 21 weeks, quantitative magnetic 
resonance (qMR) analysis (EchoMRI, Houston, TX) was done on a randomly 
selected subset of animals (n = 10/group) to obtain percent body fat and lean 
mass. At 22 weeks on the diet, all the mice were fasted for 12 hours and blood 
samples were collected from the retro-orbital venous plexus. After coagulating at 
room temperature for 30 minutes, blood samples were centrifuged at 9,300 × g 
for 5 minutes. Serum was separated, then snap-frozen and stored at −80°C until 
assayed for hormones. At 23 weeks on the diet, randomly selected mice (control, 
n = 7; control + LEU, n = 6; CR, n = 6; and CR + LEU, n = 7) were fasted for 12 
hours and anesthetized by CO2 inhalation. Blood was collected by cardiac 
puncture, and pancreata were collected and stored for analyses other than those 
outlined in this manuscript. One mouse from the control + LEU group died, and 
one mouse from the CR group died before week 23. All remaining mice 
(n = 15/group) were subcutaneously injected into the right flank with 500,000 
Panc02 cells (kindly provided by Dr. J. Schlom, National Cancer Institute, 
Bethesda, MD, USA) suspended in serum-free McCoy’s 5A medium. Once 
palpable, tumors were measured weekly with calipers, and tumor volume was 
approximated using the formula for an ellipsoid (4/3πr12r2). 
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At 27 weeks on the diet, mice were fasted for 12 hours and then 
anesthetized by CO2 inhalation. They then underwent cardiac puncture for blood 
collection and were subsequently killed by cervical dislocation. Pancreatic tumors 
were harvested and either snap-frozen in liquid nitrogen and stored at −80°C, or 
fixed with 10% neutral-buffered formalin overnight, switched to 70% ethanol, 
paraffin embedded, subsequently used for immunohistochemical analyses 
 
Serum hormones 
After study termination, serum insulin and leptin levels were analyzed 
using Lincoplex™ bead-based multiplexed assays (Millipore, Billerica, MA, USA; 
MADPK-71 K-07). Serum adiponectin and IGF-1 were quantified by singleplex 
assay kits (Millipore; MADPK-71 K-ADPN and RMIGF187K, respectively). All 
assays were analyzed using a BioRad Bioplex™ analyzer (BioRad, Hercules, 
CA, USA) according to manufacturer’s directions. 
 
Immunohistochemical analyses 
Formalin-fixed tissues were embedded in paraffin, cut into 4-μm thick 
sections, and processed for immunohistochemistry at the Histology Core 
Laboratory at The U.T. M.D. Anderson Cancer Center, Science Park Research 
Division (Smithville, TX, USA). Antibodies used for immunohistochemistry were 
optimized by core personnel using positive and negative controls for each 
analysis. Slides were deparaffinized in xylene and sequentially rehydrated in 
ethanol to water. Endogenous peroxidase activity was quenched with 3% 
hydrogen peroxide for 10 minutes. Antigen retrieval required microwaving slides 
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with 10 mM citrate buffer. Nonspecific binding was blocked by treating sections 
with Biocare blocking reagent (Biocare Medical, Concord, CA, USA) for 30 
minutes at room temperature, followed by incubation with primary antibody diluted 
in blocking buffer overnight at 4°C. The following primary antibodies and dilutions 
were used: phospho-S6 ribosomal proteinS235/236 (Cell Signaling, Danvers, MA, 
USA; 1:100); phospho-mTORSer2448 (Cell Signaling; 1:50); phospho-ACCSer79(Cell 
Signaling; 1:50); Ki-67 (Dako, Carpinteria, CA, USA; 1:200); cyclin D1 (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA; 1:500); and cleaved caspase-3 (R&D 
Systems, Minneapolis, MN, USA; 1:500). Slides were washed twice in PBS, 
incubated for 30 minutes with secondary antibody, washed two times with PBS, 
stained with diaminobenzidine (BioGenex, Fremont, CA, USA) and counterstained 
with hematoxylin. Images were captured by the Aperio ScanScope XT (Aperio 
Technologies, Vista, CA, USA) and staining was quantified using the Aperio 
ImageScope (Aperio Technologies). For Ki-67, phospho-mTOR, and cyclin D1 
quantification, automated algorithms were used to determine negative or positive 
nuclear staining. The percentage of positive cells was obtained with 20× objective 
in pancreatic tumor sections. Positive staining was defined as 1+, 2+, and 3+ for 
cyclin D1 and phospho-ACC. Positive staining for phospho-mTOR was defined as 
only 2+ and 3+ due to its high baseline phosphorylation. Cleaved caspase-3 
(CC3) was quantified as the average area of positively stained cells, with positive 
staining defined as at least 70% of a 100 μm × 100 μm section. For all proteins, 





In vitro studies 
Panc02 cells were cultured in a 37°C incubator under 5% CO2 with 
McCoy’s 5A media with glutamine (HyClone, Logan, UT, USA) and 3 g/L glucose 
but without BCAA, and then supplemented with penicillin/streptomycin, 
nonessential amino acids, sodium pyruvate, HEPES, 10% heat-inactivated FBS 
(HyClone), and physiological levels of leucine, isoleucine, and valine (MP 
Biomedicals, Santa Ana, CA, USA) (108). For western blotting, approximately 
100,000 Panc02 cells were seeded in 6-well plates and allowed to settle overnight 
in McCoy’s 5A media with 10% FBS. Cells were then treated with McCoy’s 5A 
plus 10% FBS with or without leucine supplementation and McCoy’s 5A plus 1% 
FBS with or without leucine supplementation (MP Biomedicals, Santa Ana, CA, 
USA). For western blot analysis, cells were treated for 20 min with 0.3 mM leucine 
after 3 hours of media pretreatment. 
 
Western blotting 
Panc02 cells were lysed on ice for 1 hour in RIPA buffer (Sigma, St. Louis, 
MO, USA) with protease inhibitor tablet (Roche Applied Sciences, Indianapolis, IN, 
USA) and phosphatase inhibitor cocktails II and III (Sigma). Protein lysates (40 μg) 
were resolved by SDS-PAGE using 6%, transferred to PVDF membranes (Bio-
Rad, Hercules, CA, USA) overnight at 25 volts and blocked for 1 hour at room 
temperature with LI-COR Blocking Buffer (LI-COR Biotechnologies, Lincoln, NE, 
USA). Membranes were incubated overnight at 4°C with primary antibody (from 
Cell Signaling unless otherwise stated) diluted in 5% BSA (Santa Cruz) and 
specific for: phospho-ACCSer79 (1:1000), β-actin (1:10000; Sigma), phospho-
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AMPKαT172 (1:1000), cleaved caspase-3 (1:1000), phospho-mTORSer2448 (1:1000), 
phospho-p70S6KT389 (1:1000), and phospho-S6 ribosomal 
proteinSer235/236 (1:1000). β-actin was used as a loading control for all antibodies. 
After three washes (5 minutes each) in 0.1% Tween-20/PBS (PBS-T), membranes 
were incubated for 1 hour at room temperature in species-specific secondary 
antibody (LI-COR) diluted (1:5000) in LI-COR Blocking Buffer. Following two 
washes in PBS-T and one wash in PBS, membranes were scanned using the 
Odyssey infrared fluorescent imaging system (LI-COR). Densitometry was 
performed using LI-COR software (LI-COR). Relative levels of proteins were 
calculated from three biological replicates. 
 
Cell proliferation assay 
Cell viability was measured by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT) Cell Proliferation Assay Kit (Trevigen, 
Gaithersburg, MD; 4890-025-K). In 96-well plates, Panc02 (1500 cells/well) in 
media were allowed to adhere overnight. Each well was filled with fresh treatment 
media supplemented with different amounts of FBS (10% or 1%) and leucine (0 or 
0.3 mM). The cells were then incubated for 24 h at 37°C, exposed to fresh 
treatment media after the removal of old media, and incubated for an additional 24 
h. MTT was added at a 1:10 ratio for 2 h, then the liquid was aspirated and 100 μL 
of dimethyl sulfoxide (DMSO) was added to lyse the cells and dissolve the solid 
residue. The optical density of each well at 570 nm and 690 nm, a reference 
wavelength, was determined using the Synergy 2 Multi-Detection Microplate 
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Reader and Gen5 Data Analysis Software (Fisher Scientific, Pittsburgh, PA). 
Relative cell viability was then calculated using the absorbance of cells grown in 
media with 10% FBS and no leucine supplementation for normalization. Data 
shown represent the average of three biological replicates. 
 
Statistical analysis 
 Statistical analyses were conducted using GraphPad Prism (GraphPad 
Software, La Jolla, CA). Temporal differences between groups with respect to 
body weight and energy intake were assessed using repeated measures analysis; 
final measurements were compared using one-way ANOVA and Newman-Keul’s 
post hoc test of significance. Blood glucose levels at each time point were 
compared using one-way ANOVA followed by Newman-Keul’s post hoc test of 
significance, and overall blood glucose differences were compared by performing 
a one-way ANOVA on calculated areas under the curve followed by Newman-
Keul’s post hoc test of significance. Pretumor serum hormone levels, percent body 
fat, lean mass, and fasting glucose at week 21 were compared by one-way 
ANOVA followed by Newman-Keul’s post hoc test of significance. Final 
measurements of ex vivo tumor volume and immunohistochemical staining of all 
antibodies were also compared among the groups by one-way ANOVA followed 
by Newman-Keul’s post hoc test of significance. To compare the effects of leucine 
supplementation in media with either 10% FBS or 1% FBS, western blot 
densitometry and relative cell viabilities at their respective time points were 




Effects of calorie restriction and leucine supplementation on body 
composition, glucose, homeostasis, and serum hormones 
Male C57BL/6 mice were fed a control diet with or without leucine 
supplementation, or a 30% CR diet with or without leucine supplementation, for 27 
weeks (including 21 weeks of diet before GTTs and qMRs were performed). 
Relative to the control mice, the CR mice had significantly reduced caloric intake 
(n = 22/group; p < 0.001), body weight (n = 22/group; p < 0.001), body fat 
(n = 10/group; p < 0.001), and lean mass (n = 10/group; p < 0.001), irrespective of 
leucine supplementation (Figure 2.1A-D). 
 At 21 weeks of study, the CR group without leucine supplementation, 
relative to controls without leucine supplementation, displayed enhanced glucose 
clearance as assessed by GTT (n = 10/group; p < 0.05), with blood glucose 
concentrations peaking in 15 minutes in CR mice and 30 minutes in control mice 
following glucose bolus (Figure 2.1E). Leucine supplementation significantly 
decreased glucose clearance in the context of the high-calorie control diet 
(n = 10/group; p < 0.001), but did not significantly alter glucose uptake in the 
context of the CR diet (n = 10/group; p > 0.05) (Figure 2.1E). Even at 6 weeks, 
leucine supplementation showed the same trend of inhibiting glucose clearance in 
mice on the control diet (see Figure 2.6). The CR diet group without leucine 
supplementation showed significantly lower fasting serum glucose levels relative to 
the controls (control group, n = 14; CR group, n = 15; p < 0.001) (Figure 2.1F), and 
leucine supplementation further reduced glucose levels in the CR mice 
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(n = 15/group; p < 0.001), but did not affect glucose levels in control mice (control 
group, n = 14; control group with leucine supplementation, n = 15; p > 0.05). 
The CR mice without leucine supplementation, relative to the control mice 
without leucine supplementation, had significantly lower serum levels of IGF-1 
(control group, n = 9; CR group, n = 10; p < 0.001) (Figure 2.1H) and leptin (control 
group, n = 9; CR group, n = 10; p < 0.001) (Figure 2.1I) and higher levels of 
adiponectin (control group, n = 9; CR group, n = 10; p < 0.001) (Figure 2.1J) but did 
not have significantly altered levels of insulin (control group, n = 9; CR group, 
n = 10; in p > 0.05) (Figure 2.1G). Leucine supplementation lowered IGF-1 in the 
control group (n = 9/group; p < 0.001) and reduced adiponectin (n = 10/group; p < 
0.05) in the CR mice, but caused no other alterations to the levels of the other 




Figure 2.1. Effects of calorie restriction (CR) and/or leucine (LEU) supplementation on body 
composition, glucose tolerance, and hormones. (A)Caloric intake and (B) body weight of 
C57BL/6 male mice on control and CR diets with and without leucine supplementation reported until 
glucose tolerance test (GTT) and quantitative magnetic resonance imaging (qMRI) were performed. 
(C) qMRI quantification of body fat and (D) lean mass between mice fed control or CR diets with and 
without leucine supplementation for 21 weeks. (E) GTT performed after 21 weeks on diet. 
(F) Fasting glucose levels after 21 weeks on diet (prior to tumor injection. (G-J) Serum hormone 
analyses after 21 weeks on diet (prior to tumor injection) of (G) insulin, (H) IGF-1, (I) leptin, 
and (J) adiponectin. All data are presented as the mean with error bars indicating the SD (A,B) or 
SEM (C-J). Differences are considered significant if p < 0.05. Within the same graph, bars with 
different letters are significantly different. Abbreviations: CON, control diet; CR,calorie restriction 
diet; LEU, leucine-supplemented diet. 
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Effects of calorie restriction and/or leucine supplementation on Panc02 tumor 
growth and apoptosis 
 To interrogate whether leucine supplementation modulates murine 
pancreatic cancer cell growth in control mice, and/or impacts the anticancer 
response to CR, we injected mice from each diet group with Panc02 cells at week 
23 and monitored tumor growth during the next 4 weeks. The final mean ex 
vivo tumor volume from CR mice, both with and without leucine supplementation, 
was significantly smaller than control mice (n = 14/group; p < 0.001). However, 
leucine supplementation resulted in significantly larger tumors in both the control 
and CR diet groups, relative to each diet’s respective nonsupplemented group 
(control group and control with leucine supplementation group, n = 14; p < 0.01) 
(CR group, n = 14; CR group with leucine supplementation, n = 13; p < 0.001) 
(Figure 2.2A). 
 The influence of energy balance and leucine supplementation on cell 
proliferation was assessed in tumor tissues by immunohistochemical staining 
against Ki-67 (Figure 2.2B). While CR significantly reduced cell proliferation, 
relative to control diet, in nonsupplemented mice (n = 5/group; p < 0.001), leucine 
supplementation significantly increased cell proliferation relative to the respective 
nonsupplemented mice within both diet groups (n = 5/group; p < 0.001). The 
amount of Ki-67 staining in the leucine-supplemented CR group was augmented to 
the level of the nonsupplemented control group (n = 5/group; p < 0.001). 
Leucine supplementation in the CR group enhanced tumor proliferation more 
than it did tumor burden (Figure 2.2A,B), suggesting that final tumor size was 
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influenced by both proliferation and apoptosis. Based on immunohistochemical 
analysis of tumors, we found no appreciable levels of CC3 in tumors from mice not 
supplemented with leucine; however, leucine supplementation in both the control 
and CR diet groups resulted in marked CC3-positive areas (n = 5/group; p < 0.05) 
(Figure 2.2B). Leucine supplementation in the CR group resulted in much higher 
levels of apoptosis with 9.8 percent of the tumor composed of apoptotic areas in 
the CR group compared to 1.6 percent in the control group (Figure 2.2B). This 
increase in apoptosis could explain why leucine supplementation in the CR group, 
despite an equivalent level of proliferation as the control group, resulted in 
restrained tumor growth. Although apoptosis occurred in tumors of mice that 
consumed leucine-supplemented diets, 0.3 mM leucine supplementation in vitro did 
not significantly affect CC3 levels (Figure 2.7) due to 1% FBS only partially 




Figure 2.2. Effects of leucine supplementation on Panc02 tumor growth and apoptosis. 
(A) Differences in tumor volume between mice on control and calorie restriction (CR) diets with and 
without leucine (LEU) supplementation 4 weeks after tumor cell injections. (B) Comparison of 
immunohistochemical analyses performed on tumor sections for Ki-67 and cleaved-caspase 3 
(CC3). Scale bars represent 200 μm. Tumor volume is presented as mean ± SD, and Ki-67 and CC3 
data are presented as mean ± SEM. Differences are considered significant if p < 0.05. Within the 
same graph, bars with different letters are significantly different. Abbreviations: CON, control diet; 






CR and leucine supplementation have differential effects on energy 
responsive signaling intermediates 
 The effects of energy balance and leucine supplementation on mTOR 
signaling were assessed by immunohistochemical analyses of the levels of 
phospho (p)-mTOR, p-ACC (a marker of AMPK activity, an upstream inhibitor of 
mTOR), and p-S6 and cyclin D1 (both downstream mTOR targets). Based on this 
analysis, we found that tumors from CR mice without leucine supplementation, 
relative to tumors from control mice without leucine supplementation, displayed 
increased levels of p-ACC (n = 5/group; p < 0.05) and reduced levels of p-mTOR 
(n = 5/group; p < 0.05) and its downstream effector, p-S6 ribosomal protein 
(n = 5/group; p < 0.001). Additionally, tumors from CR mice, relative to tumors from 
control mice, showed significantly reduced levels of cyclin D1 (n = 5/group; p < 
0.05) (Figure 2.3A). 
 Leucine supplementation in the control diet did not significantly alter 
amounts of these energy responsive intermediates. However, leucine 
supplementation in the CR diet significantly reduced p-ACC (n = 5/group; p < 0.001) 
and increased p-mTOR (n = 5/group; p < 0.05), p-S6 (n = 5/group; p < 0.05), and 
cyclin D1 (n = 5/group; p < 0.05) to levels comparable to the non-supplemented 




Figure 2.3. Effects of calorie restriction (CR) and/or leucine (LEU) supplementation on energy 
responsive signals in Panc02 tumors. (A) Comparison of immunohistochemical analyses on 
tumor sections for phospho-mTOR, phospho-S6, cyclin D1, phospho-ACC. Scale bars represent 
200 μm. All data are presented as the mean ± SEM. Differences are considered significant if p < 
0.05. Within the same graph, bars with different letters are significantly different. Abbreviations: 





Effect of leucine supplementation on Panc02 cell lines 
 To confirm the proliferative effect of leucine supplementation seen in vivo, in 
vitro analyses were performed using the Panc02 cell line. To model the growth 
factor restrictive environment in CR mice relative to the overweight control mice as 
seen in Figure 2.1H, we grew the cells in media with either 1% FBS or 10% FBS. 
Supplementing media with 1% FBS has been used to mimic serum growth factor 
reduction found in calorie-restricted mice (109). In the growth factor-rich 
environment of media with 10% FBS, cell viability was significantly increased by 
~30% with 0.3 mM leucine supplementation (p < 0.05) (Figure 2.4A). Leucine 
supplementation also increased cell viability by ~30% in the growth factor-restricted 
environment of media with 1% FBS (p < 0.01) (Figure 2.4B). These 30% increases 
are similar to the increases in Ki-67 seen when comparing mice on leucine-
supplemented diets to their respective nonsupplemented controls (Figure 2.2B). 
This 0.3 mM concentration of leucine were chosen based on experiments showing 
that: i) serum leucine increased by 0.3 mM in mice consuming a leucine-
supplemented diet (110); and ii) cell viability of Panc02 cells significantly increased 





Figure 2.4. Effects of leucine supplementation on viability of Panc02 tumor cells. (A-
B) Comparison of relative viability of cells grown in media with either (A) 10% fetal bovine serum 
(FBS) or (B) 1% FBS as assessed by MTT assays after 48 hours of 0.3 mM leucine 
supplementation (* = p < 0.05, ** =  p < 0.01). All data are presented as the mean ± SEM. Differences 

















Effect of leucine supplementation on mTOR pathway intermediates 
 In order to understand the differential response to leucine supplementation 
between the diet groups with respect to mTOR signaling, in vitro analyses were 
performed using Panc02 cell lines. Western blot analyses for the energy responsive 
intermediates p-AMPK, p-ACC, p-mTOR, p-p70S6K, and p-S6 revealed that the 
effects of leucine supplementation on cell signaling intermediates were impacted by 
growth factor availability. In the growth factor-rich environment of media with 10% 
FBS, supplementation with 0.3 mM leucine had no effect on phosphorylated AMPK, 
ACC, mTOR, p70S6K, or S6 ribosomal protein (Figure 2.5A,B). In the 1% FBS 
setting, leucine supplementation had no effect on phosphorylated AMPK or ACC, 
but did significantly increase phosphorylated mTOR (p < 0.05) and its downstream 
effector S6 ribosomal protein (p < 0.05). Another downstream effector of mTOR, p-
p70S6K, was also increased with leucine supplementation in the 1% FBS setting, 






Figure 2.5. Effects of leucine supplementation on energy responsive signals of Panc02 tumor 
cells. (A-C) Western blot analysis of phosphorylated AMPK, ACC, mTOR, p70S6K, and S6 after 20 
minutes of 0.3 mM leucine administration after pretreatment with respective media for 3 hours. Data 
shown are representative blots from three biological replicates, and images for each protein are 
from the same blot. (B-C) Relative phosphorylation of p-AMPK, p-ACC, p-mTOR, p-p70S6K, and p-
S6 in cells grown in media with either (A) 10% FBS or (B) 1% FBS with or without leucine 
supplementation (* = p < 0.05). All data are presented as the mean ± SEM. Differences are 




Findings in this report demonstrate for the first time that dietary leucine 
supplementation increases growth of pancreatic tumors. More specifically, we 
show that leucine supplementation not only enhances the pro-tumorigenic nature 
of a high calorie, high carbohydrate control diet, but also partially overcomes the 
well-established anticancer effects of CR. The mechanisms underlying these 
leucine-induced protumor effects may be diet-dependent, suggested by increased 
glucose availability in overweight mice and increased activation of the mTOR 
protein synthetic pathway in CR mice. 
Mice administered the leucine-supplemented control diet developed the 
largest tumors and had the highest level of tumor cell proliferation of all four 
groups. The increased tumor burden observed in the leucine-supplemented control 
group (relative to controls without leucine supplementation) occurred without 
significant changes in tumoral apoptosis or mTOR activation, as evidenced by 
unchanged levels of both p-AMPK, an upstream inhibitor of mTOR, and p-S6, a 
downstream effector of mTOR. In overweight control mice, high basal levels of 
circulating IGF-1 and tumoral mTOR activity are consistently found (Lashinger 
2011). This high level of activity likely blunted any further increase in mTOR 
activation in response to leucine supplementation in the control diet, suggesting a 
biological threshold was attained. This concept of a biological threshold for mTOR 
phosphorylation was substantiated using Panc02 cancer cells in vitro, because 
mTOR activation was only enhanced in response to leucine under growth factor 
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restrictive conditions (1% FBS) and not growth factor-abundant conditions (10% 
FBS). The enhanced tumor growth in the leucine-supplemented control group 
cannot be explained by changes in mTOR signaling in the tumor, but was 
associated with greater glucose availability (reduced fasting insulin levels and 
diminished glucose clearance). High levels of glucose have been shown to 
increase proliferation in multiple pancreatic cancer cell lines by stimulating glucose 
consumption and metabolism (111-112). Although the noted effects on insulin 
levels in the control group contradict the putative characteristics of leucine as an 
insulin secretagogue and enhancer of blood glucose disposal in patients with type 
2 diabetes (113), recent evidence suggests that leucine’s effects on glucose 
sensitivity differ depending on physiologic context, i.e., diabetic versus non-diabetic 
state (114). In a physiologic scenario, leucine stimulates mTOR activity in the β-
cells of the pancreas and promotes proliferation and thus insulin secretion (114). 
On the other hand, chronic β-cell hyperfunction, a consequence of excessive 
leucine exposure, results in accelerated β-cell apoptosis and eventual secretory 
deficiency through a negative feedback loop involving the mTOR-dependent 
inhibition of IRS-1 (115). Indeed, a diet consisting of high levels of leucine 
combined with saturated fatty acids results in insulin resistance in rodents (116), 
and chronic infusion of amino acids at high concentrations induces insulin 
resistance in humans (117). Leucine supplementation did not induce insulin 
resistance in mice on the CR regimen. CR has been shown to decrease basal 
p70S6K activation, which may have protected against mTOR-dependent β-cell 
hyperfunction (118). Taken together, our data suggest that control tumors obtained 
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a leucine-induced growth advantage because of increased glucose availability as a 
consequence of either impaired insulin secretion or function. 
Mice administered the CR diet without leucine supplementation had the 
smallest tumors and lowest level of tumor cell proliferation, while mice fed the 
leucine-supplemented CR regimen (relative to CR mice without leucine 
supplementation) had increased tumor growth to levels intermediate between the 
unsupplemented mice on the CR and control diets. Leucine supplementation in the 
CR diet, relative to CR alone, also increased tumor cell proliferation (to the levels 
observed in control mice), and increased apoptosis. It is not uncommon to observe 
increases in both cell proliferation and cell death in the same tumor, as seen in the 
tumors of mice on the CR diet. In fact, a number of dominant oncogenes that 
increase proliferation through induction of aberrant growth signals, also induce 
apoptosis (119). Thus, leucine-induced dysregulation of growth signals, such as 
mTOR activation, in a setting of low-energy substrates and growth factors in 
response to a CR regimen, may explain the observed increases in apoptosis, 
tumor cell proliferation (to control levels), and partial rescue of tumor burden in the 
leucine-supplemented CR mice. This rescue of tumor burden was only partial, 
because leucine significantly increased proliferation. As previously stated, high 
levels of mTOR activity support proliferation and survival of pancreatic cancer 
cells, and CR consistently results in decreased activation of mTOR in pancreatic 
tumors (89). In contrast to tumors from the leucine-supplemented control group, we 
found that tumors from the leucine-supplemented CR group demonstrated marked 
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increases in mTOR activation, as evidenced by lower levels of p-AMPK and higher 
levels of p-S6 and cyclin D1, without changes in fasting insulin levels and glucose 
clearance. The maintenance of physiologic insulin secretion in the CR mice was 
perhaps due to the protection of β-cells by chronic CR, a strategy that has been 
shown to increase β-cell proliferation in rats (118). Taken together, our data 
suggest that CR tumors obtained a leucine-induced growth advantage because of 
increased mTOR activation. 
In conclusion, this report establishes that dietary leucine supplementation, 
irrespective of energy balance status, promotes pancreatic tumor growth. These 
findings suggest caution regarding the clinical use of leucine supplementation for 













Figure 2.6. Effects of leucine supplementation on glucose tolerance at 6 weeks. Glucose 
tolerance test (GTT) performed after 6 weeks on diet (n = 10/group; p < 0.001 between control with 
leucine supplementation and the calorie restriction (CR) groups; p < 0.05 between the control 





Figure 2.7. Effects of single BCAA supplementation on apoptosis of Panc02 tumor 
cells. Western blot analysis of cleaved caspase-3 protein levels after 24 hours of either 0.3 mM 
leucine, isoleucine, or valine administration. Data shown are representative blots from three 
biological replicates. Relative protein levels of cleaved caspase-3 were quantified by densitometry 
using LI-COR Odyssey software. All data are presented as the mean ± SEM. Differences are 




Figure 2.8. Effects of different doses of leucine supplementation on Panc02 tumor cell 
viability. Comparison of relative cell viability as assessed by MTT assays after 48 hours of leucine 
supplementation (* = p < 0.05). All data are presented as the mean ± SEM. Differences are 






β-Hydroxy-β-methylbutyrate supplementation inhibits pancreatic 
tumor growth and preserves muscle mass 
Introduction 
Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of 
cancer-related deaths in the United States. A major contributor to this statistic is 
cancer cachexia, which is present in about 80% of pancreatic cancer patients (49). 
Cachexia is characterized by involuntary weight loss and breakdown of adipose 
and muscle tissue. This condition lowers quality of life, reduces response to 
gemcitabine, the primary chemotherapy for pancreatic cancer, and increases 
mortality rate (120-121). The negative effects of cachexia are specifically tied to 
muscle loss, because muscle breakdown is an independent predictor of reduced 
cancer survival, even after controlling for body mass index (BMI), age, and tumor 
stage (4). Low muscle mass is also an independent prognostic factor of poor 
overall and recurrence-free survival of pancreatic cancer patients after resection 
(122).  
 Due to the obesity epidemic in Western society, a growing proportion of 
pancreatic cancer patients at the start of therapy have a body mass index (BMI) in 
the obese range (>30 kg/m2). Many of these individuals have sarcopenic obesity, 
a condition characterized by the presence of high fat mass but low muscle mass 
(sarcopenia). Recent studies have reported that obesity in the presence of 
sarcopenia is predictive of morbidity and mortality in pancreatic cancer patients (4), 
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at least in part because sarcopenic obesity increases the odds of developing 
cancer cachexia (5). Obesity is connected to these outcomes through hormones 
involved in growth signaling, such as insulin and insulin-like growth factor-1 (IGF-1) 
and through pro-inflammatory cytokines, such as TNF-α. Obese mice, compared 
with lean mice, have higher circulating levels of these factors, which activate 
specific intracellular signaling pathways (123-125).  
Insulin and IGF-1 bind to their respective receptors on the cell surface, 
which leads to the activation of several downstream signaling pathway 
components including PI3K, Akt, and the mechanistic target of rapamycin (mTOR).  
mTOR then phosphorylates and activates its downstream proteins 4EBP1 and 
ribosomal protein S6, both of which increase protein translation and eventually 
lead to cell growth and proliferation. Therefore, if mTOR is activated within tumor 
cells, it increases tumor growth, and if mTOR is activated within muscle fibers, it 
increases muscle fiber size. Rapamycin, a specific mTOR inhibitor, reduces 
pancreatic tumor growth and inhibits muscle growth in mice (89, 126). 
Pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), 
are produced mainly by macrophages (127) and bind to their cell surface receptors 
leading to the degradation of the inhibitor of NF-κB (IK-kB) and the subsequent 
translocation of NF-κB to the nucleus, where it regulates the transcription of many 
different genes, including genes involved in cell survival and the cell cycle (128). 
Thus, NF-κB activation within PDAC cells is typically pro-tumorigenic, and 
inhibition of NF-κB reduces PDAC growth in mice (129). In muscle tissue, NF-κB 
specifically increases the transcription of the atrogene MuRF-1, a protein involved 
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in the ubiquitin-proteasome system of muscle breakdown, which leads to muscle 
atrophy (130). Inhibition of NF-κB prevents cancer-induced muscle atrophy (131).  
The PI3K/Akt/mTOR and NF-kB signaling pathways, which are highly 
activated in an obese environment, may explain why patients with sarcopenic 
obesity often have enhanced tumor growth coupled with muscle loss. A major 
challenge in treating PDAC patients with cachexia is finding interventions that take 
into account effects on both tumor and muscle. However, as muscle loss is the 
driving force behind the negative consequence of cachexia, most treatments have 
focused on either increasing muscle protein or inhibiting muscle protein breakdown 
(132). This focus on protein has led many researchers to study the building blocks 
of protein, the amino acids and their metabolites. β-hydroxy-β-methylbutyrate 
(HMB), the metabolite of the branched-chain amino acid leucine, has begun to 
emerge as a strong potential candidate for increasing muscle mass (132). HMB 
supplementation increases muscle growth through mTOR activation (133) and also 
attenuates muscle protein degradation through the prevention of NF-κB activation 
(56). However, mTOR and NF-κB are involved in tumor growth as well, and the 
effects of HMB supplementation on PDAC growth are unknown.  
To establish that HMB exerts positive effects on muscle and PDAC, in the 
context of gemcitabine (an FDA-approved chemotherapy drug for PDAC; 134), we 
tested the effects of HMB supplementation on the growth of muscle and 
transplanted Panc02 mouse pancreatic tumors with and without gemcitabine 
chemotherapy. The study was performed on both normo-weight and diet-induced 
obese (DIO) mice to assess the impact of obesity, shown previously to enhance 
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Materials and Methods 
Mice and dietary interventions 
All experiments were conducted under a protocol approved by the 
Institutional Animal Care and Use Committee at the University of Texas at Austin. 
All diets were purchased from Research Diets (New Brunswick, NJ, USA). One 
hundred twenty male C57BL/6 mice were obtained from Charles River Breeding 
Laboratories (Wilmington, MA, USA) at 6 to 8 weeks of age, and upon arrival were 
doubly-housed in a semi-barrier facility at the Dell Pediatric Research Institute and 
fed the control diet during a one-week acclimation period.  
Mice were then singly-housed and randomized (n = 60 per group) to either 
continue on the control (CON) diet with 10% kcal from fat (D12450J from Research 
Diets; New Brunswick, NJ, USA) or receive the diet-induced obesity (DIO) diet with 
60% kcal from fat (D12492 from Research Diets) for 10 weeks. The diets, 
consumed ad libitum, matched in both type and amount of protein, vitamins, and 
minerals, and only differed in the percentage of fat and carbohydrate.  
Energy intake and body weight for each mouse were recorded weekly. At 
the beginning of week 10, randomly selected mice (n = 30 per diet group) were 
fasted for 6 h, and then tail clips for fasting glucose and retro-orbital bleeds for 
blood collection were performed. Blood glucose levels were measured with a 
Contour glucometer (Bayer HealthCare LLC, Mishawaka, IN, USA). After 
coagulating at room temperature for 30 minutes, blood samples were centrifuged 
at 12,000 x g for 5 minutes. Serum was separated, then snap-frozen and stored at 
-80°C until assayed for hormones and pro-inflammatory cytokines. After a 48h rest 
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period, all mice were subcutaneously injected into the right flank with 250,000 
Panc02 cells (generously provided by Dr. J. Schlom, National Cancer Institute, 
Bethesda, MD, USA) suspended in serum-free McCoy’s 5A medium (Sigma, St. 
Louis, MO, USA).  
Also at week 10, dietary HMB supplementation began (CON, n = 30; CON + 
HMB, n = 30; DIO, n = 30; DIO + HMB, n = 30). Ca-HMB (HMB) was purchased 
from Metabolic Technologies, Inc. (Ames, IA, USA) and was incorporated into the 
diets at a concentration of 1% (w/w) dietary HMB supplementation to achieve a 
daily amount of 0.5 g HMB/kg body weight. This amount was chosen based on the 
calculations done by Kim, et al, who converted the human supplemental dose (6 
g/day) to an appropriate rodent dose after taking into account rodent metabolic rate 
and average daily food consumption (135).  
Once palpable, tumors were measured biweekly with calipers and 3 
gemcitabine (50 mg/kg each) injections were administered intraperitoneally every 3 
days. At week 15, all mice were fasted for 6-8 h and then anesthetized by CO2 
inhalation. They underwent tail clips for fasting glucose, cardiac punctures for 
blood collection, and then were killed by cervical dislocation. Pancreatic tumors 
and gastrocnemius muscle were harvested and either snap-frozen in liquid 
nitrogen and stored at -80°C, or fixed with 10% neutral-buffered formalin for 48 
hours, switched to 70% ethanol, and paraffin embedded. The frozen tissue was 
subsequently used for PCR and western blot analysis, and the paraffin-embedded 




Serum Hormones and Cytokines 
 Serum collected at week 10 (before dietary HMB supplementation and 
tumor cell injection) was analyzed for hormones and cytokines. Insulin levels were 
measured using the Bio-Plex Pro Mouse Diabetes Insulin Single Plex Assay (Bio-
Rad, Hercules, CA, USA) IGF-1 levels were measured using the Millipore 
MILLIPLEX Rat/Mouse IGF-1 Single Plex Assay (Millipore, Billerica, MA, USA), 
and the pro-inflammatory cytokines interleukin (IL)-1β, IL-6, IL-10, IL-17A, IFN-γ, 
and TNF-α were measured using the Bio-Plex Pro Mouse Cytokine Th17 Panel A 
6-Plex Assay (Bio-Rad). Analysis was performed on the Bio-Rad Bio-Plex 200 
Analysis System (Bio-Rad). 
 
Tumor and Muscle H&E and Immunohistochemistry 
Paraffin-embedded tumors and skeletal muscle were cut into 4-µm thick 
sections, and processed for either hematoxylin and eosin (H&E) or 
immunohistochemical (IHC) staining at the Histology Core Laboratory at the UT-
MD Anderson Cancer Center, Science Park Research Division (Smithville, TX, 
USA). The muscle tissue was cut into cross-sections, so the thickness of each 
individual fiber could be quantified. All antibodies used for immunohistochemistry 
were optimized by core personnel using positive and negative controls for each 
analysis. 
Slides were deparaffinized in xylene and sequentially rehydrated in ethanol 
to water. Endogenous peroxidase activity was quenched with 3% hydrogen 
peroxide for 10 minutes, and antigen retrieval was achieved by microwaving slides 
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with 10 mM citrate buffer. Nonspecific binding was blocked by treating sections 
with Biocare blocking reagent (Biocare Medical, Concord, CA, USA) for 30 minutes 
at room temperature, followed by incubation with primary antibody diluted in 
blocking buffer overnight at 4°C. The following primary antibodies and dilutions 
were used: phospho-S6 ribosomal proteinS235/236 (Cell Signaling, Danvers, MA, 
USA; 1:100); and Ki-67 (Dako, Carpinteria, CA, USA; 1:200). Slides were washed 
twice in PBS, incubated for 30 minutes with secondary antibody, washed two times 
with PBS, stained with diaminobenzidine (BioGenex, Fremont, CA, USA) and 
counterstained with hematoxylin.  
Images were captured by the Aperio ScanScope XT (Aperio Technologies, 
Vista, CA, USA) and staining was quantified using the Aperio ImageScope (Aperio 
Technologies). Automated algorithms were used to determine positive nuclear or 
cytoplasmic staining of Ki-67 and phospho-S6, respectively. The percentage of 
positive cells (or positive intensity) was obtained with 20x objective in 4 different 
areas of the PDAC sections. Necrotic sections were not included. For all proteins, 
the positive staining was averaged per treatment group (n = 6 randomly selected 
slides per group).   
 
Gene Expression Microarray Analysis 
 Total RNA samples were extracted by RNeasy Kit (Qiagen, Valencia, CA, 
USA) from homogenized tumors and hybridized to the Affymetrix Mouse Gene 2.1 
ST 24-Array plate. The quality of the RNA sample was checked using Agilent 
bioanalyzer. The mRNA expression raw data were quantile normalized and the 
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signal values were transformed to the log2 value. The comparative analysis 
between different group samples was carried out using the t-test (p-values) and the 
Benjamini-Hochberg False Discovery Rate (FDR) correction (adjusted p-values) 
using R. Differentially expressed genes between experimental groups were 
determined if the p-values were < 0.05 and if the fold changes were > 1.5. The 
expression level of selected genes were combined and zero-transformed to the 




Real-time quantitative PCR was performed to validate the microarray 
results. Total RNA was reverse-transcribed to cDNA using High-Capacity cDNA 
reverse transcription kit (Fisher Scientific, Waltham, MA, USA) with random 
hexamers. The relative level of gene expression was measured and normalized to 
β-actin by qPCR using PowerUp SYBR Green PCR Mix (Applied Biosystems, 
Austin, TX, USA).  
Quantitative PCR was also done to determine how HMB supplementation 
affected muscle degradation signaling. Total RNA was isolated from 
gastrocnemius muscle (n = 5 per group) using TRIzol reagent (Invitrogen, Grand 
Island, NY, USA), and 2 µg of RNA per sample was reverse transcribed using the 
High-capacity cDNA Reverse Transcription Kit (Applied Biosystems). RNA 
extraction and reverse transcription were performed according to the respective 
manufacturer’s protocol. Gene expression levels were quantified by mixing 
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optimized amounts of Power SYBR Green PCR Master Mix (Applied Biosystems), 
forward and reverse primers, and cDNA in 96-well plates and performing RT-PCR 
reactions in an Eppendorf instrument (Santa Clara, CA). Relative differences in 
gene expression were normalized to the housekeeping gene, GAPDH, and 
analyzed using the 2-ΔΔCT method, as described by Schmittgen and Livak (136). All 
primers used are listed in Figure 3.7. 
 
Muscle Fiber Size 
Cross-sectional images of H&E-stained gastrocnemius muscle were 
analyzed using Fiji (ImageJ from NIH). Muscle breakdown due to cancer cachexia 
is largely restricted to fast-twitch (type II) glycolytic fibers (137), so only fast-twitch 
muscle fibers were analyzed. This was done by marking regions of the small and 
dark slow-twitch fibers, the large and light fast-twitch fibers, and the slide 
background to train the Advanced Weka Segmentation classifier included in Fiji 
and help it distinguish between these fibers before analysis (138).  
Muscle fiber size was determined using the minimal Feret’s diameter, 
because this parameter has been proven to be the most robust against 
experimental errors, such as the orientation of the sectioning angle (139). There 
were 200-400 muscle fibers analyzed per slide (n = 6 per group) resulting in a total 
of greater than 8000 muscle fiber measurements. The minimal Feret’s diameters of 





Western Blot Analyses 
Protein lysates were obtained by cutting frozen gastrocnemius muscle into 
10-30 mg pieces on dry ice and then placing them into bead beater tubes with 0.5 
mL of freshly prepared RIPA buffer (Sigma) with a protease inhibitor tablet (Roche 
Applied Sciences, Indianapolis, IN, USA) and phosphatase inhibitor cocktails II and 
III (Sigma). Then, the tubes were half-filled with 2.5mm diameter zirconia/silica 
beads (Biospec Products, Bartlesville, OK, USA). Homogenization was performed 
using the Mini-BeadBeater-1 (Biospec Products), where the tubes were shaken at 
4800 rpm for 10 seconds and left on ice for 30 seconds. The cycle of shaking and 
cooling was repeated 5 times until homogenization was complete. After quick 
centrifugation, the protein homogenate was placed into a new Eppendorf tube and 
left to incubate in ice for 30 minutes with occasional vortexing. To shear DNA, the 
samples were then sonicated 5 times for 10 seconds with a 30 second rest on ice 
between each sonication. Then, the samples were centrifuged at 14,000 rpm for 15 
min at 4°C, and the supernatant was transferred to a new tube. 
Protein lysates (100 µg) were resolved by SDS-PAGE using precast 6% 
polyacrylamide gels followed by transfer to PVDF membranes (Bio-Rad) overnight 
at 25 volts and blocked for 1 hour at room temperature with LI-COR Blocking 
Buffer (LI-COR Biotechnologies, Lincoln, NE, USA). Membranes were incubated 
overnight at 4°C with primary antibody (from Cell Signaling unless otherwise 
stated) diluted in 5% BSA (Santa Cruz) with 0.2% Tween-20. The primary 
antibodies were specific for: GAPDH (1:10,000), MuRF-1 (0.1 µg/mL; Abcam), 
phospho-S6 ribosomal proteinSer235/236 (1:500), and S6 ribosomal protein (1:1000).  
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GAPDH was used as a loading control for all antibodies. After three washes (10 
minutes each) in 0.1% Tween-20/PBS (PBS-T), membranes were incubated for 1 
hour at room temperature in species-specific secondary antibody (LI-COR) diluted 
(1:5000) in LI-COR Blocking Buffer with 0.2% Tween-20 and 0.01% SDS.  
Following two washes in PBS-T and one wash in PBS, membranes were 
scanned using the Odyssey infrared fluorescent imaging system (LI-COR). 
Densitometry was performed using LI-COR software (LI-COR). Raw values were 
compared between groups only if they were on the same membrane, and then 
those values, normalized to GAPDH levels, were used to calculate the overall 
relative levels of proteins (n = 4 per group). Values of phosphorylated proteins 




Statistical analyses were conducted using GraphPad Prism (GraphPad Software, 
La Jolla, CA). All comparisons between the CON group and the DIO group were 
analyzed using unpaired, two-tailed t-tests. Final differences between groups with 
respect to body weight were compared using one-way ANOVA and Tukey’s post 
hoc test of significance. Fasting glucose, serum hormone levels, and serum 
cytokine levels were compared by one-way ANOVA followed by Tukey’s post hoc 
test of significance. Significance regarding complete tumor regression was 
obtained by comparing the number of mice with tumor to mice without tumor and 
analyzing using Fisher’s exact test. Final measurements of ex vivo tumor weight 
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and volume, immunohistochemical staining of phospho-S6, and muscle fiber size 
(Feret’s diameter) were also compared among the groups by one-way ANOVA 
followed by Tukey’s post hoc test of significance. Western blot densitometry was 
compared by one-way ANOVA followed by Fisher’s LSD test of significance. 






Effects of the high-fat, diet-induced obesity regimen (DIO) on body weight, 
fasting glucose, and hormones 
Relative to the control (CON) mice, the obese (DIO) mice had significantly 
higher body weight (n = 57-58 per diet group; p < 0.05) (Figure 3.1A), higher 
fasting glucose (n = 27-30 per diet group; p < 0.05) (Figure 3.1B), higher fasting 
insulin (n = 25-30 per diet group; p < 0.0001) (Figure 3.1C), and higher fasting IGF-




Figure 3.1. Effects of the high-fat, diet-induced obesity regimen (DIO) on body weight, 
fasting glucose, and hormones. (A) Body weight (n = 57-58 per diet group) of C57BL/6 male 
mice on control and DIO diets reported until week 10 on diet prior to tumor cell injection. (B-D) 
Serum analyses of fasting (B) glucose (n = 27-30 per diet group), (C) insulin (n = 25-30 per diet 
group) and (D) IGF-1 (n = 24-25 per diet group). All data are presented as the mean ± SD (A) or 
mean ± SEM (B-D). Differences are considered significant if p < 0.05. If groups were compared to 
all other groups, different letters were used to indicate significantly different values. If groups were 
compared only to a control group, * were used to indicate significance, where * = p < 0.05, ** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001.  
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Effects of HMB supplementation on skeletal muscle size and signaling 
At the end of the study DIO mice had smaller muscles compared with the 
CON mice, and HMB supplementation increased muscle size regardless of diet (n 
> 1,000 fibers per group; p < 0.05 between bars with different letters) (Figure 
3.2A). HMB supplementation decreased MuRF-1 expression in the CON mice, but 
increased MuRF-1 expression in the DIO mice (n = 5 per group; p < 0.05 between 
bars with different letters) (Figure 3.2B). Neither diet nor HMB supplementation 
had an effect on protein levels of MuRF-1 (n = 4 per group; p > 0.05) (Figure 3.2C-
E). A marker of muscle growth and mTOR signaling, phospho-S6, increased in the 
DIO mice compared with the CON mice, although this difference did not achieve 
statistical significance. HMB supplementation increased phospho-S6 levels 




Figure 3.2. Effects of HMB supplementation on skeletal muscle size and signaling. (A-B) 
Results of HMB supplementation within both the control and DIO diets at study termination on 
muscle (A) minimal Feret’s diameter, the most robust measurement that correlates with muscle 
fiber size (n > 1,000 per group) and (B) gene expression of the atrogene, MuRF-1 (n = 5 per 
group). (C-E) Protein levels of the atrogene MuRF-1 when comparing (C) control and DIO diets 
only, (D) HMB supplementation within the control diet, and (E) HMB supplementation within the DIO 
diet (n = 4 per group). (F-H) Levels of phospho-S6, a protein downstream of active mTOR, when 
comparing (F) control and DIO diets only, (G) HMB supplementation within the control diet, and (H) 
HMB supplementation within the DIO diet (n = 4 per group). All data are presented as mean ± SEM. 
Differences are considered significant if p < 0.05. If groups were compared to all other groups, 
different letters were used to indicate significantly different values. If groups were compared only to 
a control group, * were used to indicate significance, where * = p < 0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001.  
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Effects of HMB supplementation on glucose levels, Panc02 tumor growth, 
and tumor signaling 
 DIO mice had increased glucose levels compared with the CON mice, and 
HMB supplementation decreased glucose regardless of diet, although not 
statistically significantly in the DIO mice (n = 13-15 per group; p < 0.05 between 
bars with different letters) (Figure 3.3A). The DIO mice also had significantly larger 
tumors than the CON mice, and HMB supplementation significantly decreased 
tumor size in the DIO mice (n = 13-15 per group; p < 0.05 between bars with 
different letters) (Figure 3.3B). The results for tumor cell proliferation were similar 
to tumor volume. The DIO diet increased Ki-67 significantly compared with the 
CON diet. Moreover, HMB supplementation significantly decreased Ki-67 in the 
DIO mice (n = 6 per group; p < 0.05 between bars with different letters) (Figure 
3.3C). The DIO diet increased phospho-S6 significantly compared with the CON 
diet, while HMB supplementation had no significant effect on phospho-S6 in the 
CON or DIO mice (n = 6 per group; p < 0.05 between bars with different letters) 




Figure 3.3. Effects of HMB supplementation on glucose levels, Panc02 tumor growth, and 
tumor signaling. (A-D) Results of HMB supplementation within both the control and DIO diets at 
study termination on (A) fasting glucose (n = 13-15 per group), (B) tumor volume (13-15 per group), 
(C) a marker of proliferation, Ki-67 (n = 6 per group), and (D) a protein downstream of active 
mTOR, phospho-S6 (n = 6 per group). Scale bars represent 200 µm. All data are presented as 
mean ± SEM. Differences are considered significant if p < 0.05, as indicated by different letters 






Effects of HMB supplementation on Panc02 tumor response to gemcitabine 
To determine whether dietary HMB supplementation affects the efficacy of 
gemcitabine treatment, we added HMB into the diets of half the mice in each 
original diet group (CON or DIO) and injected Panc02 tumor cells into all mice at 
week 11. After two weeks of tumor growth, we administered gemcitabine 
intraperitoneally every 3 days until study termination. The comparisons were done 
within each respective diet group (CON or DIO) in order to distinguish between any 
diet-differential effects of HMB on gemcitabine treatment.  
After the first two weeks of tumor growth, palpations were performed twice 
weekly and tumors were present in all mice. However, at the end of the growth 
period, four weeks post tumor-injection, mice had tumors that had regressed so 
much in size, they were not found when surgery was performed. This complete 
tumor regression occurred in 5 out of 14 of the CON mice treated with gemcitabine 
alone and in 5 out of 15 of the CON mice treated with gemcitabine and HMB (p < 
0.05) (Figure 3.4A). Complete tumor regression did not occur in the DIO mice with 
gemcitabine alone, but it did occur in 3 out of 14 of the DIO mice treated with 
gemcitabine and HMB, although results did not achieve statistical significance (p > 
0.05) (Figure 3.4B).  
 At study termination, we compared the effects of either gemcitabine alone 
or gemcitabine with HMB supplementation on tumor volume and Ki-67, a marker of 
proliferation. The tumors excised from the CON mice were small and variable, and 
there were no statistically significant differences between the groups, although 
gemcitabine alone and in combination with HMB did decrease the average tumor 
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volume (n = 13-15 per group; p > 0.05) (Figure 3.4C). The difference between 
tumor size was much easier to distinguish in the DIO mice. Gemcitabine treatment 
decreased tumor volume, but not significantly; however, the addition of HMB 
supplementation to gemcitabine decreased average tumor volume significantly 3.5-
fold (n = 13-15 per group; p < 0.05 between bars with different letters) (Figure 
3.4D). 
In the CON mice, gemcitabine treatment alone increased Ki-67 (n = 6 per 
group; p < 0.05 between bars with different letters) (Figure 3.4E). In the DIO mice, 
both gemcitabine alone and in combination with HMB decreased Ki-67 levels (n = 




Figure 3.4. Effects of HMB supplementation on Panc02 tumor response to gemcitabine. (A-F) 
Results of treating mice in the same diet group with gemcitabine alone (GEM) or in conjunction with 
HMB supplementation at study termination on (A-B) complete tumor regression (n = 13-15 per 
group), (C-D) tumor volume (n = 13-15 per group), and (E-F) a immunohistochemical marker of 
proliferation, Ki-67 (n = 6 per group). Scale bars represent 200 µm. All data are presented as mean 




Transcriptional response to diet and HMB supplementation 
 After demonstrating HMB inhibited tumor growth and had no detrimental 
effects on chemotherapy, we investigated possible mechanisms. The literature 
suggested two possibilities: 1) HMB could increase mTOR and growth signaling, 
and 2) HMB could inhibit NF-κB and inflammatory signaling. We showed HMB 
supplementation did not have a significant effect on tumor mTOR activation (Figure 
3.3d), and although HMB could be inhibiting inflammatory signaling within the 
tumor, we showed no effect of diet on circulating pro-inflammatory cytokines 
(Figure 3.8). This led us to perform a microarray, a global analysis, on tumors from 
mice consuming the CON or DIO diet with and without HMB supplementation.  
 Although some genes were similarly regulated by the DIO diet and HMB 
supplementation (Figure 3.5A), a significant number of genes were upregulated by 
the DIO diet and downregulated by HMB supplementation (Figure 3.5B-C). Most of 
the genes suppressed by HMB were in the olfactory receptor family, and a few 
genes were involved in tumor proliferation and metastasis (Cldn9 and Pax2) and 
lipogenesis (Acsm1 and Lpcat4). Overall, the DIO diet increased expression of 
these genes in the tumor, while HMB supplementation decreased expression of 





Figure 3.5. Transcriptional response to diet and HMB supplementation. (A-B) Heatmap of (A) 
all and (B) specifically chosen transcriptional response of tumor tissue from mice consuming the 
control or DIO diet with or without HMB supplementation. (B) qPCR validation of specific genes 
upregulated by the DIO diet and downregulated by HMB supplementation. 
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HMB supplementation-specific transcriptional response 
This cluster of genes, which refers to a family of related genes, was 
upregulated by HMB supplementation regardless of diet (Figure 3.6A). The 
majority of these genes were either T cell receptor genes or involved in T cell-
specific activity (CD4). Immunohistochemistry performed on tumor tissue for CD3, 
a universal T cell marker, revealed significant T cell infiltration of the tumor in 
response to HMB supplementation (Figure 3.6B). Further, quantitative PCR 
performed on tumor tissue for CD8a and CD8b showed the DIO diet significantly 
decreased cytotoxic CD8+ T cell expression, while HMB in the DIO diet 





Figure 3.6. HMB supplementation specific transcriptional response. (A) Heatmap of 
transcriptional response of tumor tissue from mice consuming the control or DIO diet with or without 
HMB supplementation. qPCR validation of specific genes downregulated by the DIO diet and 
upregulated by HMB supplementation. (B) Immunohistochemistry of a marker of T cell infiltration, 
CD3 (n = 6 per group). Scale bars represent 100 µm. (C) qPCR of cytotoxic CD8+ T cell gene 
expression within the tumor tissue. All data are presented as mean ± SEM. Differences are 






 Our findings demonstrate for the first time that dietary HMB supplementation 
decreases the growth of pancreatic tumors and preserves skeletal muscle mass in 
DIO mice. More specifically, we show that HMB supplementation not only inhibits 
the pro-tumorigenic environment of a high-fat, diet-induced obesity regimen (DIO), 
but also increases mTOR activation and growth only in muscle but not in tumor 
tissue. The mechanisms underlying these effects of HMB on tumor growth may be 
diet-dependent, suggested by a greater effect on glucose levels in the CON tumors 
and a greater effect on mTOR activation in the DIO tumors.   
 HMB supplementation in the CON mice exerted its own effects on muscle 
and tumor. In this diet group, HMB supplementation significantly increased muscle 
fiber size, decreased MuRF-1 gene expression, had no effect on MuRF-1 protein 
levels, and increased muscle mTOR activation. All these results support the 
enhanced muscle growth, except for the MuRF-1 protein levels. It is not 
uncommon when mRNA levels are unable to predict protein levels, especially 
when the protein is involved in a cyclical event, such as muscle regeneration (140). 
Decreased atrogene expression, but no significant difference in protein, may 
indicate HMB was beginning to inhibit atrophy and that the effects had not yet 
become apparent at the protein level. With respect to tumor, HMB had no effect on 
tumor size, proliferation, or tumor mTOR activation, although it did decrease 
glucose levels. Since this diet did not result in high circulating growth factors, the 
tumors did not grow quickly, even in the untreated group. Thus, even if HMB were 
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exerting an anti-tumorigenic effect by decreasing available glucose (77), it may not 
have been apparent in the slow-growing CON tumors.  
 HMB supplementation in the DIO mice exerted its own effects on muscle 
and tumor as well. In this diet group, HMB supplementation significantly increased 
muscle fiber size, increased MuRF-1 gene expression, had no effect on MuRF-1 
protein levels, and increased muscle mTOR activation. All these results support 
enhanced muscle growth, except for the MuRF-1 gene expression levels. In an 
obese setting, especially with consistently high glucose and insulin (Figure 3.1B-
C), insulin resistance can occur, and this can cause muscle degradation (141). 
HMB has been shown to attenuate insulin resistance (142), and thus, attenuate the 
associated muscle breakdown. HMB may have slowly increased muscle synthesis 
over time, eventually leading to a large amount of protein synthesis near the end of 
the 4-week supplementation period. Then, when protein levels became high in the 
muscle, MuRF-1 expression was transiently increased to recycle some of the 
excess protein. MuRF-1 expression has been shown to be transient (143). Taken 
together, this may explain the HMB-induced increase in MuRF-1 gene expression 
with no change in protein levels. With respect to tumor, HMB significantly 
decreased tumor size and tumor cell proliferation, while slightly decreasing glucose 
and tumor mTOR activation. All these results support each other and show dietary 
HMB supplementation alone can affect pancreatic cancer.  
HMB supplementation did not harm gemcitabine efficacy within the CON 
diet. Complete tumor regression occurred in a significant number of mice on the 
CON diet when they were treated with gemcitabine, and their average tumor size 
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was lower than the untreated mice. The addition of HMB did not change these 
outcomes, and HMB even managed to slightly decrease tumor cell proliferation 
seen in the gemcitabine-treated CON mice. The gemcitabine-induced increase in 
Ki-67 was surprising. In this case, the CON tumors that did not regress may have 
become gemcitabine-resistant. Pancreatic cancer cells able to survive high-dose 
gemcitabine treatment end up expressing increased levels of stem cell genes, 
show characteristics similar to epithelial-mesenchymal transition, and retain 
proliferative capability (144). Due to their resistance, the remaining CON tumors 
may have become more aggressive and proliferated at a faster rate.  
 HMB supplementation enhanced gemcitabine efficacy within the DIO diet as 
evidenced by tumor regression and decreased tumor size. HMB may have been 
particularly synergistic with gemcitabine in this setting, because of the specific 
environment established by the obesigenic diet. Obesity is associated with 
resistance to gemcitabine in pancreatic cancer (Figure 3.4C-D) and breast cancer 
(145). This obesity-induced chemoresistance is associated with various factors, 
one of which is increased production of IL-1β within the tumor microenvironment, 
leading to the activation of the angiotensin II type-1 receptor (AT1) signaling 
pathway and elevated desmoplasia. Desmoplasia is an overproduction of 
extracellular matrix tissue, which blocks the penetration of gemcitabine into tumors 
(146). Although we found no evidence of the DIO diet increasing circulating 
inflammatory markers (Figure 3.8), this does not preclude the involvement of 
inflammation within or near the tumor. IL-1β can be produced by pancreatic stellate 
cells, tumor-associated macrophages, and pancreatic tumor cells (147). HMB has 
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been shown to decrease inflammatory signaling within cancer cells (56), so HMB 
may have been able to overcome some resistance to gemcitabine and increase its 
efficacy by reducing local inflammatory signaling. 
 As revealed by the gene expression microarray analysis, the DIO diet 
compared with the CON diet upregulated genes involved in olfaction and tumor 
proliferation and metastasis, while HMB supplementation within the DIO diet 
downregulated these genes. Although olfactory receptors (ORs) have been 
traditionally relegated to olfaction, studies have shown the existence of ectopic 
ORs, or ORs outside of the olfactory sensory system, suggesting possible 
nontraditional roles. In fact, our results support previous work showing a high-fat 
diet, similar to our DIO diet, upregulated olfactory and cancer-related genes in fat 
and muscle tissue of mice (73). Recent research has also shown connections 
between ORs and some cancers. Increased expression of ORs has also been 
seen in various cancers, including gastrointestinal neuroendocrine, prostate, and 
lung cancer (148). Upregulation of OR51E1 promotes prostate tumor growth and 
correlates with cancer progression (149-150), and a mutation in OR2W3 is 
associated with pancreatic ductal adenocarcinoma development (76). Further, 
knockdown of the OR2A1 and OR2A4 receptors in HeLa cervical cancer cells and 
in HCT116 colon cancer cells inhibits cell division (151). Our data showed the DIO 
diet increased OR gene expression and pancreatic tumor growth, while HMB 
supplementation decreased OR gene expression and tumor growth. Taken 
together, this suggests HMB may inhibit pancreatic tumor growth by reducing 
tumor-specific ORs.  
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 The microarray further revealed HMB supplementation upregulated T cell 
receptor genes, genes involved in T cell activity, and overall T cell infiltration in 
both diet groups. The DIO diet compared with the CON diet specifically decreased 
cytotoxic CD8+ T cell tumor infiltration, while HMB increased cytotoxic CD8+ T cell 
tumor infiltration in the DIO group. For over ten years, researchers have shown the 
positive correlation between cytotoxic CD8+ T lymphocyte infiltration in tumors and 
enhanced survival of patients with colorectal cancer, breast cancer, melanoma, 
ovarian cancer, and non-Hodgkin’s lymphoma (152). As such, the cytotoxic CD8+ 
T cells have been known as a key component of an effective anti-tumor immune 
response (153). Our data showed the DIO diet decreased cytotoxic CD8+ T cell 
tumor infiltration and increased pancreatic tumor growth, while HMB increased 
cytotoxic CD8+ T cell tumor infiltration and decreased tumor growth. Taken 
together, this suggests HMB may inhibit pancreatic tumor growth by stimulating the 
immune system and generating T cells that localize and kill tumor cells.  
 Although our transplant model of pancreatic cancer provides insight into 
how HMB supplementation affects tumor growth, it cannot provide any information 
with respect to tumor development. In order to study how HMB affects the 
development of PDAC, future studies could be performed in our spontaneous 
model of pancreatic cancer, the LSL-Kras(G12D)/Pdx-1-Cre/Ink4a/Arf(lox/+) mice. 
These mice have an activating Kras mutation and an Ink4a/Arf deficiency, the 
combination of which promotes the formation of pancreatic intraepithelial neoplasia 
(PanIN) lesions and eventually PDAC (123, 154-155). Moreover, our transplant 
model is also limited, because it is not a model of cancer cachexia. There are no 
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models of pancreatic cancer cachexia available, however, there are well-
established models of colon and breast cancer cachexia. These models involve the 
subcutaneous injection of specific cell lines (C 26 for colon, and Walker 256 for 
breast) that cause cachexia. To study how HMB affects cancer cachexia and 
cachectic symptoms (weight loss, muscle breakdown, hypoglycemia, 
hyperlacticidemia, hypertriacylglycerolemia, and loss of glycogen stores) one of 
these models could be selected.  
In conclusion, this report establishes that dietary HMB supplementation 
preserves muscle mass, irrespective of diet, has no detrimental effects on 
gemcitabine treatment, and inhibits pancreatic tumor growth, reduces tumor-
specific olfactory receptor expression, and increases cytotoxic CD8+ T cell tumor 
infiltration in an obese setting. These findings suggest HMB is a strong candidate 
for the purpose of lean muscle enhancement in cachectic cancer patients, although 
caution should still be exercised due to the differences between murine and human 
metabolism. Additional research is needed to ascertain the impact amino acids and 
their metabolites have on cancer growth and muscle repair; the identification of 
natural supplementation approaches to spare muscle in cachectic cancer patients; 










Gene Forward primer (5’-3’) Reverse primer (5’-3’) 
Cldn9 GTATCGTACTCACCGCAGGG AGCCCCCAGTTCTCTCTTGA 
Olfr1393 TTCTGTGAGATGCCTGTTTTCCT AGGCACTGCAACAATCACCAC 
Olfr1128 ACACATCCTGTACATTCCAACTG ATGTATCTGAGCAGGAGAGGGC 
Lpcat4 GCCTCTCCCTCTGTCAGTTC GGTATCTGGGAGGTGCTTCG 
Acsm1 CTGAAGTGGAGTGTGGGGAC ATGCGATACCCGGAAGCATT 
Pax2 GCGAGGAAGATGTGTCTGAGG TCGGGATAGGAAGGACGCTC 
Trav9n-4 GATGCCCAAGCTCAGTCAGT AAGGTGTCGCAGAGTAGGAA 
Trav14n-3 TGGGAAGGAGAGACCGCAAT TCGGACACTGAACGTATGGC 
Trav9n-3 GGAGTGAATGGCTTTGAGGC GAAGTACACAGCCCAGTCGC 
CD4 ATCCAGAGGGGTGAACCAGA TGCCTGGCGCTGTTGG 
CD8a TACCACAGGAGCCGAAAGCG CCTGGCGGTGCCATTTTACA 
CD8b AGACTCAAGACGGCCCTTTC GGAAGGACATCAACCACAGTC 
MuRF-1 ACGAGAAGAAGAGCGAGCTG CTTGGCACTTGAGAGAGGAAGG 
GAPDH CGTGTTCCTACCCCCAATGT ATGTCATCATACTTGGCAGGTTTCT 





Figure 3.8. Levels of pro-inflammatory cytokines in serum of mice on the CON or DIO diet after 10 













Leucine and HMB supplementation affect pancreatic cancer 
cell proliferation and olfactory receptor expression 
Introduction 
 Pancreatic cancer is projected to be the 2nd leading cause of cancer-related 
deaths by the year 2020 (156). This is due, in part, to cachexia, which occurs in 
80% of pancreatic cancer patients (49). Cachexia is characterized by involuntary 
weight loss and significant breakdown of lean muscle and adipose tissue, and it 
reduces the patients’ quality of life, their response to chemotherapy, and their 
survival rate (120). The muscle breakdown especially contributes to these 
consequences, as it is an independent predictor of reduced cancer survival, after 
controlling for weight, age, and tumor stage (4). Muscle breakdown is also an 
independent prognostic factor of poor overall and recurrence-free survival of 
pancreatic cancer patients even after resection of the tumor (122).  
 Due to the significant correlations between muscle breakdown and poor 
outcomes, the research for cachexia treatment focuses on compounds that affect 
muscle protein synthesis/breakdown (49-50). This focus on protein led researchers 
to study amino acids, the building blocks of protein. Branched-chain amino acids 
increase muscle protein synthesis almost to the same extent as an entire meal, 
and the branched-chain amino acid leucine alone can stimulate muscle protein 
synthesis (51). Increased focus on leucine led to the discovery of one of its 
metabolites, β-hydroxy-β-methylbutyrate (HMB). Leucine and HMB are particularly 
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relevant as potential cachexia treatments, because they lead to the 
phosphorylation and activation of the mechanistic target of rapamycin (mTOR) in 
skeletal muscle (53). mTOR is a serine/threonine protein kinase integral to protein 
synthesis through its phosphorylation of several downstream proteins involved in 
protein translation, including p70S6 kinase (p70S6K), ribosomal protein S6 (S6), 
and eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) (157). 
When it is activated in muscle, protein synthesis and hypertrophy occur (158). 
However, mTOR activation is correlated with increased pancreatic tumor growth 
(77), while mTOR inhibition decreases pancreatic tumor growth and has been 
shown to cause tumor regression in a specific subtype (60,159).   
 If leucine and HMB are to be administered to pancreatic cancer patients 
with cachexia to enhance muscle growth through mTOR signaling, studies need to 
be conducted to ascertain their effects on both muscle and tumor tissue. As most 
studies focus on the effects of leucine and HMB on muscle, we chose to determine 
the effects of these supplements on pancreatic ductal adenocarcinoma (PDAC) 
tumor growth using a murine transplant model (77, Chapter III). We found leucine 
supplementation increased PDAC tumor growth in lean and overweight mice, while 
only enhancing mTOR signaling within the tumors of lean mice (77). Then, we 
found HMB supplementation decreased PDAC tumor growth, while having no 
significant effect on mTOR signaling within the tumor. Instead, HMB 




Although ORs are traditionally believed to play roles only in the olfactory 
system, a few studies have shown dysregulation of ORs in various cancer types 
(148). Upregulation of OR51E1 enhances prostate tumor growth (149-150). 
Knockdown of the OR2A1 and OR2A4 receptors in cervical and colon cancer cells 
inhibits cell proliferation (151). Further, a mutation in OR2W3 is correlated with 
PDAC (76). These findings support the idea that ORs could regulate tumor growth. 
In the present study, our goals were to investigate if the direct effects of 
leucine and HMB on pancreatic cancer growth were: 1) similar to the in vivo 
results, 2) associated with mTOR signaling, 3) associated with OR gene 
expression, and 4) comparable to the effects of common OR agonists. We used 
two murine (Panc02 and NB508) and two human (Panc-1 and MiaPaca-2) PDAC 
cell lines to evaluate the effects of leucine and HMB on cell growth and growth 
signaling. These cells were also treated in media with different concentrations of 
fetal bovine serum (FBS) to simulate an in vitro growth factor-rich and growth 
factor-restricted environment, similar to the internal environments of the 
obese/overweight and lean mice, respectively. We then evaluated the effects of 
leucine and HMB on gene expression to determine their regulation, if any, of 
specific ORs. Finally, we determined the effects of OR agonists on pancreatic 
cancer cell proliferation. Our findings suggest that leucine and HMB are able to 
directly affect pancreatic cancer cell growth and growth signaling and that their 




Materials and Methods 
Cell culture treatments 
The murine PDAC cells, Panc02 and NB508, and the human PDAC cells, 
Panc-1 and MiaPaca-2, were cultured in a 37°C incubator under 5% CO2 in RPMI 
media with glutamine (Sigma-Aldrich, St. Louis, MO, USA) and 3 g/L glucose. The 
media was supplemented with penicillin/streptomycin, nonessential amino acids, 
sodium pyruvate, HEPES, and 10% heat-inactivated FBS (Sigma-Aldrich).  
For MTT assays, Panc02 and NB508 cells (1,500 cells/well) and Panc-1 
and MiaPaca-2 cells (3,000 cells/well) were seeded in 96-well plates. After 24 
hours, the old media was removed and fresh RPMI media was added, 
supplemented with different amounts of FBS (10% or 1%), leucine or HMB (0, 1, 2, 
or 4 mM), and OR agonists (5 µM, 10 µM, 50 µM, or 100 µM).  The cells were then 
incubated for 48 h at 37°C. Leucine was from MP Biomedicals (Santa Ana, CA, 
USA), HMB was from Metabolic Technologies, Inc. (Ames, IA, USA), and all OR 
agonists were from Sigma-Aldrich. Optimal doses of leucine and HMB were used 
in later experiments. 
For western blotting, Panc02 and NB508 cells (200,000 cells/well) and 
Panc-1 and MiaPaca-2 cells (400,000 cells/well) were seeded in 6-well plates. 
After 24 hours, the old media was removed and fresh RPMI media was added, 
supplemented with different amounts of FBS (10% or 1%). After 4 hours of 




For the microarray, Panc02 cells (100,000 cells/well) were seeded in 6-well 
plates. After 24 hours, the old media was removed and fresh RPMI media with 1% 
FBS was added, supplemented with different amounts of leucine or HMB (4 mM). 
The cells were then incubated for 24 h at 37°C. 
 
Cell proliferation assay 
 MTT reagent, thiazolyl blue tetrazolium bromide (Sigma), was added to 
treated cells at a 1:10 ratio for 2 hours, then 180 µL of liquid was aspirated and 
100 µL of dimethyl sulfoxide (DMSO) was added to lyse the cells and dissolve the 
purple formazan crystals. The optical density of each well at 540 nm and 690 nm, a 
reference wavelength, was determined using the Synergy 2 Multi-Detection 
Microplate Reader and Gen5 Data Analysis Software (Fisher Scientific, Pittsburgh, 
PA, USA). Relative cell viability was then calculated using the absorbance of cells 
grown in media without treatment for normalization. Data shown represent the 
average of three biological replicates. 
 
Western blot analysis 
 Treated cells were lysed on ice for 1 hour in RIPA buffer (Sigma) with 
protease inhibitor tablet (Roche Applied Sciences, Indianapolis, IN, USA) and 
phosphatase inhibitor cocktails II and III (Sigma). Protein lysates (20 µg) were 
resolved by SDS-PAGE using 6%-12% gels, transferred to nitrocellulose 
membranes (Bio-Rad, Hercules, CA, USA) for 15 hours at 25 volts and blocked for 
1 hour at room temperature with LI-COR Blocking Buffer (LI-COR Biotechnologies, 
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Lincoln, NE, USA). Membranes were incubated overnight at 4°C with primary 
antibodies diluted in 5% BSA (Santa Cruz). The primary antibodies were from Cell 
Signaling, Danvers, MA, USA, unless otherwise stated, and were specific for: β-
actin (1:1000), mTOR (1:1000), phospho-mTORSer2448 (1:1000), p70S6K (1:1000), 
phospho-p70S6KT389 (1:1000), S6 ribosomal protein (1:1000), and phospho-S6 
ribosomal proteinSer235/236 (1:1000). After three 5-minute washes in 0.1% Tris-
Buffered Saline Tween-20 (TBST), membranes were incubated for 45 minutes in 
species-specific secondary antibody (LI-COR) diluted (1:5000) in LI-COR Blocking 
Buffer. Following two washes in TBST and one wash in TBS, membranes were 
scanned using the Odyssey infrared fluorescent imaging system (LI-COR). 
Densitometry was performed using LI-COR software, and relative levels of proteins 
were calculated from three biological replicates. Raw values were compared 
between groups only if they were on the same membrane. β-actin was used as a 
loading control for all antibodies, and then all phosphorylated proteins were 
normalized to their respective non-phosphorylated protein. 
 
Microarray analysis 
Total RNA samples were extracted by RNeasy Kit (Qiagen, Valencia, CA, 
USA) from homogenized tumors and hybridized to Affymetrix Mouse Gene 2.1 ST 
24-Array plate. The quality of the RNA sample was checked using Agilent 
bioanalyzer. The mRNA expression raw data were quantile normalized and the 
signal values were transformed to the log2 value. The comparative analysis 
between different group samples was carried out using the t-test (p-values) and the 
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Benjamini-Hochberg False Discovery Rate (FDR) correction (adjusted p-values) 
using R. Differentially expressed genes between experimental groups were 
determined if the p-values were < 0.05 and if the fold changes were > 1.5. The 




Statistical analyses were conducted using GraphPad Prism (GraphPad 
Software, La Jolla, CA). When multiple treatment doses were used in the same 
experiments, pancreatic cancer cell viability was compared by one-way ANOVA 
followed by Fisher’s LSD tests of significance to compare all treated groups to the 
non-treated group. Western blot densitometry was analyzed using unpaired, two-
tailed t-tests, where the leucine- and HMB-supplemented groups were compared 







Effects of leucine supplementation on PDAC cell proliferation  
To determine the effects of direct leucine supplementation on PDAC cells, 
Panc02, NB508, Panc-1, and MiaPaca-2 cells were supplemented with different 
doses of leucine (0, 1, 2, 4 mM) within serum-rich (10% FBS) and serum-restricted 
(1% FBS) environments. In the serum-rich environment, leucine increased Panc02 
cell proliferation, but it actually inhibited MiaPaca-2 proliferation at a lower dose (n = 
3; p < 0.05) (Figure 4.1A). Then, in the serum-restricted environment, leucine 
increased Panc02, NB508, and MiaPaca-2 proliferation (n = 3; p < 0.05) (Figure 
4.1B). Overall, leucine supplementation enhanced PDAC cell proliferation at 4 mM, 
especially in the serum-restricted environment. The 4 mM dose of leucine was 




Figure 4.1. Effects of leucine supplementation on PDAC cell proliferation. (A-B) Results of MTT 
assays performed on murine and human PDAC cells after supplementation with leucine for 48 hours in 
either a (A) serum-rich or (B) serum-restricted environment (n = 3 biological replicates). All data are 
presented as mean ± SEM. Differences are considered significant if p < 0.05. Groups were compared 




Effects of HMB supplementation on PDAC cell proliferation 
To determine the effects of direct HMB supplementation on PDAC cells, 
Panc02, NB508, Panc-1, and MiaPaca-2 cells were supplemented with different 
doses of HMB (0, 1, 2, 4 mM) within serum-rich (10% FBS) and serum-restricted (1% 
FBS) environments. In the serum-rich environment, HMB decreased Panc02, Panc-
1, and MiaPaca-2 proliferation (n = 3; p < 0.05) (Figure 4.2A). Then, in the serum-
restricted environment, HMB significantly decreased Panc02, NB508, Panc-1, and 
MiaPaca-2 proliferation (n = 3; p < 0.05) (Figure 4.2B). Overall, HMB 
supplementation inhibited PDAC cell proliferation, especially at 4 mM in the serum-





Figure 4.2. Effects of HMB supplementation on PDAC cell proliferation. (A-B) Results of MTT 
assays performed on murine and human PDAC cells after supplementation with leucine for 48 hours in 
either a (A) serum-rich or (B) serum-restricted environment (n = 3 biological replicates). All data are 
presented as mean ± SEM. Differences are considered significant if p < 0.05. Groups were compared 




Effects of leucine and HMB supplementation on murine PDAC mTOR signaling 
To determine the effects of direct leucine and HMB supplementation on mTOR 
signaling within murine PDAC cells, Panc02 and NB508 cells were supplemented 
with leucine and HMB (4 mM) within serum-rich (10% FBS) and serum-restricted (1% 
FBS) environments. In the serum-rich environment, leucine did not affect mTOR 
signaling (n = 3; p > 0.05) (Figure 4.3A), and HMB only significantly decreased 
NB508 p-mTOR levels (n = 3; p < 0.05) (Figure 4.3A). In the serum-restricted 
environment, leucine did not have a statistically significant effect on mTOR signaling 
(n = 3; p > 0.05) (Figure 4.3B), although it seemed to increase mTOR signaling. On 
the other hand, HMB decreased p-mTOR and p-S6 in the NB508 cells (n = 3; p < 
0.05). Overall, the effects of leucine and HMB supplementation were more 
pronounced in the serum-restricted environment. Leucine supplementation trended in 
the direction of increased mTOR signaling, although it did not reach statistical 






Figure 4.3. Effects of leucine and HMB supplementation on murine PDAC mTOR signaling. (A-B) 
Results of western blot analyses performed on murine pancreatic cancer cells after supplementation with 
4 mM leucine or HMB for 30 minutes after pretreatment in either a (A) serum-rich or (B) serum-restricted 
environment for 4 hours (n = 3 biological replicates). All data are presented as mean ± SEM. Differences 
are considered significant if p < 0.05. Groups were compared only to the non-supplemented control 
group, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
89 
 
Effects of leucine and HMB supplementation on human PDAC mTOR signaling 
To determine the effects of direct leucine and HMB supplementation on mTOR 
signaling within human PDAC cells, Panc-1 and MiaPaca-2 cells were supplemented 
with leucine and HMB (4 mM) within serum-rich (10% FBS) and serum-restricted (1% 
FBS) environments. In the serum-rich environment, leucine did not affect mTOR 
signaling (n = 3; p > 0.05) (Figure 4.4A), and HMB only decreased Panc-1 p-mTOR 
signaling (n = 3; p < 0.05) (Figure 4.4A). Then, in the serum-restricted environment, 
leucine significantly increased Panc-1 p-p70S6K and p-S6 and MiaPaca-2 p-mTOR 
and p-S6 levels, while HMB significantly decreased Panc-1 p-S6 and MiaPaca-2 p-
mTOR levels (n = 3; p < 0.05) (Figure 4.4B). Overall, the effects of leucine and HMB 
supplementation were once again stronger in the serum-restricted environment. 





Figure 4.4. Effects of leucine and HMB supplementation on human PDAC mTOR signaling. (A-B) 
Results of western blot analyses performed on human pancreatic cancer cells after supplementation with 
4 mM leucine or HMB for 30 minutes after pretreatment in either a (A) serum-rich or (B) serum-restricted 
environment for 4 hours (n = 3 biological replicates). All data are presented as mean ± SEM. Differences 
are considered significant if p < 0.05. Groups were compared only to the non-supplemented control 
group, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
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Transcriptional response of Panc02 cells to leucine and HMB supplementation 
 Although the proliferation and mTOR signaling results were consistent as a 
whole—leucine increased proliferation and mTOR signaling, while HMB decreased 
proliferation and mTOR signaling—the Panc02 cells were not as consistent with 
these overall results. Panc02 cell proliferation was enhanced with leucine and 
inhibited with HMB; however, mTOR signaling was not as strongly affected in the 
Panc02 cells as it was in the other cells. This suggested leucine and HMB were 
possibly working through other mechanisms as well as growth signaling. To 
investigate their effects on global gene expression, a microarray was performed on 
Panc02 cells supplemented with leucine or HMB in a serum-restricted (1% FBS) 
environment.  
 As seen in Figure 5A, leucine and HMB did regulate many genes differently in 
Panc02 cells. Specifically, leucine downregulated Mir721, Fosb, Olfr487, Olfr582, 
Atp1a4, and Ap3s1-ps2, while HMB upregulated these genes. Then, HMB 
downregulated Mir709, Olfr1138, Olfr402, Adamts9, Mir337, Trav7-6, Fxyd6, Lair1, 
Olfr1034, and Mir669m-1, while leucine upregulated these genes (Figure 4.5B). One-
third of these differentially regulated genes were the OR genes, Olfr487, Olfr582, 
Olfr1138, Olfr402, and Olfr1034 (Figure 4.5C). HMB has been shown to decrease 
Panc02 tumor growth and OR expression previously (Chapter III), so it is plausible 





Figure 4.5. Transcriptional response of Panc02 cells to leucine and HMB supplementation. (A-C) 
Results of a microarray performed on Panc02 cells after 24 hour supplementation with leucine or HMB in 
a serum-restricted environment. Heat maps shown display gene expression for (A) all identifiable genes, 
(B) genes differentially regulated by HMB and leucine, and (C) specific olfactory receptor genes 
differentially regulated by HMB and leucine. 
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Effects of amyl acetate on PDAC cell proliferation 
 To interrogate whether it was plausible that a few ORs could affect PDAC cell 
proliferation, we first determined if an OR agonist had an effect. OR agonists are 
commonly used in studies to activate many ORs simultaneously at doses ranging 
from 10 µM to 1 mM, although the most common concentration is 100 µM (160-163). 
Panc02, NB508, Panc-1, and MiaPaca-2 cells were treated with various doses of the 
OR agonist, amyl acetate (0, 5, 10, 50, 100 µM), in both serum-rich (10% FBS) and 
serum-restricted (1%) environments.  
In the serum-rich environment, amyl acetate increased NB508 proliferation at 
100 µM (n = 3; p < 0.05) (Figure 4.6A), while it decreased Panc02 and MiaPaca-2 
proliferation in the serum-restricted environment (n = 3; p < 0.05) (Figure 4.6B). This 
shows amyl acetate can affect both murine and human PDAC cell lines, although the 





Figure 4.6. Effects of amyl acetate on PDAC cell proliferation. (A-B) Results of MTT assays 
performed on murine and human PDAC cells after supplementation with an OR agonist, amyl acetate, 
for 48 hours in either a (A) serum-rich or (B) serum-restricted environment (n = 3 biological replicates). 
All data are presented as mean ± SEM. Differences are considered significant if p < 0.05. Groups were 
compared only to the non-supplemented control group, where * = p < 0.05, ** = p < 0.01, *** = p < 0.001, 
**** = p < 0.0001. 
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Effects of octanal on PDAC cell proliferation 
 To further explore the effects of OR agonists on PDAC cell proliferation, 
Panc02, NB508, Panc-1, and MiaPaca-2 cells in serum-rich (10% FBS) and serum-
restricted (1%) environments were treated with various doses of octanal (0, 5, 10, 50, 
100 µM), another OR agonist commonly used in studies (160-163). Octanal at 100 
µM decreased Panc02, NB508, Panc-1, and MiaPaca-2 proliferation in the serum-
rich (n = 3; p < 0.05) (Figure 4.7A) and serum-restricted environment (n = 3; p < 0.05) 
(Figure 4.7B). Octanal was able to inhibit growth of both murine and human PDAC 
cells in both types of environments, although the growth-inhibitive effects were more 
pronounced in the serum-restricted environment. These effects of octanal are similar 




Figure 4.7. Effects of octanal on PDAC cell proliferation. (A-B) Results of MTT assays performed on 
murine and human PDAC cells after supplementation with an OR agonist, octanal, for 48 hours in either 
a (A) serum-rich or (B) serum-restricted environment (n = 3 biological replicates). All data are presented 
as mean ± SEM. Differences are considered significant if p < 0.05. Groups were compared only to the 




 The current study was conducted to determine if the direct effects of leucine and 
HMB supplementation on PDAC growth were: 1) similar to the in vivo results, 2) 
associated with mTOR signaling, 3) associated with OR gene expression, and 4) 
comparable to the effects of common OR agonists. We first began by supplementing 
leucine and HMB to two murine (Panc02 and NB508) and human (Panc-1 and 
MiaPaca-2) cell lines in serum-rich (10% FBS) and serum-restricted (1% FBS) 
environments, which simulated in vitro obese/overweight and lean environments.  
In the serum-rich environment, leucine increased Panc02 and NB508 
proliferation, but it did not have a significant effect on mTOR signaling. This is 
consistent with our previous results, where dietary leucine supplementation enhanced 
Panc02 tumor growth in overweight mice without affecting mTOR activation (77). 
Leucine did not increase mTOR activation, because mTOR was already activated at a 
high level due to the serum-rich environment. Leucine, however, did not have similar 
results in the human cells, because it inhibited MiaPaca-2 proliferation. The MiaPaca-2 
cells are human rather than murine, so they may have characteristics that make 
susceptible to leucine in a different way than the Panc02 and NB508 cells. It is known 
that the uptake of leucine occurs through a sodium-insensitive, L-type amino acid 
transporter (LAT1), and that this transporter exists in various cancer cell lines, including 
C6 glioma and and the breast cancer cell lines, MDA-MB-231 and MCF-7 (164-166). 
The MiaPaca-2 cells may have a larger amount of the LAT1 transporter, thus making 
them more sensitive to leucine supplementation. In an environment rich with growth 
factors, the addition of a large amount of leucine may have caused a negative 
98 
 
feedback loop and the inhibition of growth. It is common for signaling pathways to have 
negative feedback loops as checkpoints. In fact, the mTOR pathway, a central growth 
pathway, can be inhibited by one of its downstream proteins, S6K (167).  
Then, in the serum-restricted environment, leucine increased Panc02, NB508, 
and MiaPaca-2 proliferation along with Panc-1 and MiaPaca-2 mTOR signaling. This is 
again consistent with the results of our previous study, which showed leucine 
enhanced Panc02 tumor growth in lean mice while increasing mTOR activation (77). 
Although leucine did not significantly increase mTOR signaling within the Panc02 cells, 
it did activate this growth pathway in the human cells. These results suggest that 
leucine may be utilized for growth differently in murine PDAC cells and human cells. In 
the serum-restricted environment, human PDAC cells may use leucine mainly to 
stimulate mTOR, and the murine PDAC cells may oxidize leucine for energy instead. 
Breast and liver tumors have been shown to contain active forms of the enzymes 
involved in branched-chain amino acid catabolism, BCAAT and BCKDH (168-169), so 
it is plausible PDAC cells catabolize leucine as well.  
On the other hand, HMB had similar effects in both the serum-rich and serum-
restricted environments. In the serum-rich environment, HMB decreased Panc02, 
Panc-1, and MiaPaca-2 proliferation, while decreasing NB508 and Panc-1 mTOR 
signaling. In the serum-restricted environment, HMB decreased Panc02, NB508, Panc-
1, and MiaPaca-2 proliferation, while decreasing NB508, Panc-1, and MiaPaca-2 
mTOR signaling. These results are consistent with our previous findings that dietary 
HMB supplementation decreased Panc02 tumor growth in obese mice (Chapter III). 
However, the finding that HMB supplementation decreases mTOR signaling in 
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pancreatic cancer cells is novel. HMB has been shown to increase mTOR activation, 
especially in skeletal muscle and the myotube cell lines, C2C12 and L6 (170-171), and 
due to the similarity of its actions to leucine, there is support for HMB as an mTOR-
enhancer. However, Sabatini et al. demonstrated that the mTOR pathway has a sensor 
for leucine specifically, which explains why leucine consistently increases mTOR in 
various tissues (172). No studies have shown HMB may have a similar mTOR 
pathway-specific sensor.  
  While both leucine and HMB affected mTOR signaling in the serum-restricted 
environment, their effects on mTOR were not always consistent with their effects on 
PDAC cell proliferation, especially in the Panc02 cells. Thus, our next step was to 
explore other potential mechanisms through the analysis of global gene expression. A 
microarray was performed on Panc02 cells in serum-restricted media supplemented 
with leucine or HMB, and they were found to differentially regulate various genes. One-
third of these genes coded for ORs, which suggests OR expression is correlated with 
PDAC proliferation and may even play a role in PDAC growth. The association 
between OR expression and PDAC growth is consistent with our finding in the PDAC 
tumors of obese mice, where obesity enhanced both OR expression and PDAC growth, 
and HMB decreased both OR expression and PDAC growth (Chapter III). However, in 
the Panc02 cells, HMB did not universally downregulate ORs. Instead, leucine and 
HMB had opposing effects on Olfr487, Olfr582, Olfr1138, Olfr402, and Olfr1034. This 
suggests specific ORs may have different roles to play in PDAC proliferation. Multiple 
studies have demonstrated aberrant OR expression in cancerous tissues (148). 
OR51E1 is increased in various cancers, including gastrointestinal neuroendocrine 
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cancer (173-174), prostate cancer (149-150), and somatostatin receptor SSTR-
negative lung carcinoid tumors (175). OR51E2 is upregulated in prostate cancer and is 
thought to promote tumor growth (176-177), although Neuhaus et al. demonstrated that 
activation of OR51E2 inhibited prostate cancer cell proliferation (178). Moreover, 
different mutations in OR2W3 are associated with PDAC and autosomal dominant 
retinitis pigmentosa (76,179).  
 Before investigating if specific ORs affected PDAC proliferation, we first tested 
whether simultaneous changes in multiple ORs could affect cell growth. To do this, all 
PDAC cell lines were treated with two commonly used OR agonists, amyl acetate and 
octanal. Amyl acetate increased NB508 proliferation in the serum-rich environment, but 
it decreased Panc02 and MiaPaca-2 proliferation in the serum-restricted environment. 
Octanal was more consistent in that it decreased Panc02, NB508, Panc-1, and 
MiaPaca-2 proliferation in both the serum-rich and serum-restricted environments. 
These results show that changing the expression of multiple ORs can affect PDAC cell 
proliferation, and different OR agonists have distinct effects on PDAC cells. This is due 
to their ability to regulate different ORs, which suggests PDAC cell proliferation is 
affected by specific ORs. Amyl acetate treatment was similar to leucine 
supplementation with respect to its environment-dependent effects on PDAC 
proliferation, while octanal mirrored HMB supplementation with respect to its growth-
inhibitory effects on PDAC cells. Although the nutritional supplements and OR agonists 
may not regulate the same ORs, their similar effects on proliferation suggest ORs may 
be another link connecting leucine, HMB, and PDAC growth. 
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 In conclusion, this report establishes that leucine supplementation increases 
PDAC cell proliferation and mTOR signaling in the serum-restricted environment. On 
the other hand, HMB supplementation decreases PDAC cell proliferation and mTOR 
signaling in both the serum-rich and serum-restricted environments. Leucine and HMB 
then differentially affect OR expression within Panc02 cells, and two OR agonists have 
different effects on PDAC growth. These findings confirm HMB, not leucine, is a strong 
candidate for cancer cachexia treatment, because it inhibited both murine and human 
PDAC cell proliferation. Moreover, a potential mechanism for leucine and HMB may 







Final conclusions and future directions 
 
 
Due to the obesity epidemic in the United States and many other parts of the 
world, an increasing number of pancreatic cancer patients at the start of treatment are 
overweight or obese. Many of these patients have sarcopenic obesity, which is 
characterized by high fat mass and low muscle mass. This combination increases the 
chances of developing cancer cachexia, which is present in 80% of pancreatic cancer 
patients, and is predictive of morbidity and mortality (58,5). These consequences are 
due to both obesity, which creates a pro-tumor environment through various circulating 
factors, and muscle loss, which reduces response to chemotherapy and increases 
mortality rate (2-8). An ideal treatment for these patients would treat both the cancer 
and cachexia, as they are strongly connected, but unfortunately therapeutic regimens 
that effectively target both the cancer and the cachexia are not currently available. In 
practice, the treatment would most likely have to be two-pronged; for example 
chemotherapy for the cancer and potentially nutritional supplementation for the 
cachexia (49-50). Two potential cachexia treatments are the branched-chain amino 
acid (BCAA) leucine and its metabolite, β-hydroxy-β-methylburtyrate (HMB) due to their 
growth-enhancing and breakdown-inhibiting effects in muscle (51-56). However, we 
previously found in a preclinical model that leucine promotes pancreatic cancer growth 
(77), while to our knowledge no studies to date have explored the effects of HMB on 
pancreatic tumor growth.  
The overall aim of the project presented herein was to determine the impact of 




physiological environments (lean versus obese) or with and without chemotherapy 
(gemcitabine) and to elucidate potential mechanisms underlying these effects. From 
these studies, we were able to demonstrate the following: 1) leucine had no effect on 
lean mass in lean and overweight mice (Chapter II); 2) leucine enhanced Panc02 tumor 
growth in lean and overweight mice and increased PDAC cell proliferation in a serum-
restricted environment (Chapter II, IV); 3) leucine increased mTOR signaling within the 
Panc02 tumors of lean mice and increased mTOR signaling within PDAC cells in a 
serum-restricted environment (Chapter II, IV); 4) leucine affected olfactory receptor 
(OR) expression in PDAC cells (Chapter IV); 5) HMB preserved muscle mass in normo-
weight and obese mice (Chapter III); 6) HMB inhibited Panc02 tumor growth in obese 
mice and decreased PDAC cell proliferation in both a serum-rich and serum-restricted 
environment (Chapter III, IV); 7) HMB increased the efficacy of the chemotherapeutic 
agent gemcitabine, in obese mice (Chapter III); 8) HMB had no effect on mTOR 
signaling within the Panc02 tumors of normo-weight and obese mice (Chapter II); 9) 
HMB decreased mTOR signaling in PDAC cells in both serum-rich and serum-
restricted environments (Chapter IV); 10) HMB stimulated T cell infiltration into the 
Panc02 tumors of normo-weight mice and specifically cytotoxic CD8+ T cell infiltration 
into the Panc02 tumors of obese mice (Chapter III); 11) HMB downregulated many OR 
genes in the Panc02 tumors of obese mice and differentially regulated OR genes in 
Panc02 cells in a serum-restricted environment (Chapter III, IV). Taken together, these 
findings suggest that leucine enhances pancreatic tumor growth, and therefore may not 
be a good candidate for cancer cachexia in PDAC patients. HMB, however, inhibits 




candidate for the cancer cachexia in PDAC patients. Specifically, leucine increases 
mTOR signaling, especially in lean mice (that typically have low levels of circulating 
growth factors that can activate mTOR signaling), while HMB either has no effect on 
Panc02 tumor mTOR activation or (depending on the cell line and dose) decreases 
PDAC cell mTOR signaling. Moreover, HMB increases cytotoxic CD8+ T cell infiltration 
and decreases OR expression in Panc02 tumors. Both leucine and HMB regulated OR 
expression in PDAC cells, although we did observe differential effects of these two 
agents on specific receptors. Thus, there may be multiple mechanisms by which 
leucine and HMB differentially affect PDAC. 
While the data presented fulfills the project aims, further in vivo and in vitro 
studies could be performed to provide a more comprehensive evaluation of the effects 
of leucine and HMB on muscle and tumor. Additional in vitro studies could be 
conducted to elucidate potential mechanisms of leucine and HMB action on PDAC 
cells. Specifically, a continuation of Chapter IV would involve performing qPCR for the 
specific ORs discovered using the microarray on PDAC cells supplemented with 
leucine, HMB, amyl acetate, and octanal. This would both confirm the microarray 
results and determine if these ORs are regulated by leucine, HMB, and the OR 
agonists. Then, silencing of these ORs through specific siRNA could be performed on 
the PDAC cells. Following the silencing with MTT assays would determine if these ORs 
are mechanistically involved in PDAC cell proliferation. Thus, leucine and HMB would 





Another continuation of Chapter IV would involve determining the effects of 
leucine and HMB on metabolic parameters, specifically glycolysis and mitochondrial 
respiration. These pathways are of interest, because pancreatic cancer cells are known 
to exhibit high levels of glycolysis over mitochondrial respiration. This is called the 
Warburg effect, and studies suggest it may be due in part to mitochondrial respiration 
injury (180). Leucine and HMB have both been shown to enhance the efficiency of 
mitochondrial biogenesis in muscle. Leucine induces peroxisome proliferator-activated 
receptor beta/delta (PPARβ/δ) in myotubes and mediates PPARβ/δ-dependent 
mitochondrial biogenesis (181), while HMB increases expression of peroxisome 
proliferator-activated receptor gamma co-activator 1-alpha (PGC-1α), which induces 
genes involved in mitochondrial metabolism and biogenesis (182). Although the effects 
of leucine and HMB on pancreatic cancer cell metabolic flux has, to my knowledge, not 
previously been assessed, I hypothesize that HMB in particular may be able to shift 
PDAC cells to favor mitochondrial respiration, interrupting the Warburg effect and 
depriving these cells of the building blocks required for cell proliferation they normally 
obtain through glycolysis (183). To determine any shifts in cellular energetics, PDAC 
cells would be treated with leucine or HMB and subjected to the Seahorse XF 
Extracellular Flux Analyzer, which measures oxygen consumption rates (OCR) and 
extracellular acid release (ECAR) simultaneously. The OCR correlates with 
mitochondrial respiration, while ECAR correlates with glycolysis. This experiment would 
provide insight on how leucine and/or HMB may be changing the internal metabolic 





 Although investigating possible avenues for the effects of leucine and HMB on 
PDAC cells gives valuable mechanistic data, a clearer understanding of how these 
supplements may work in cancer patients would be gained through in vivo studies. Our 
studies used a previously-established C57BL/6 murine model of subcutaneous PDAC 
that did not have cachexia for several reasons. These mice were responsive to high-
energy and low-energy diets that would establish pro-tumor and anti-tumor 
environments; they could easily grow tumors from the syngeneic Panc02 and thus, 
maintain an intact immune system; and they have been used to demonstrate PDAC-
dependency on mTOR signaling (60). These factors were relevant when studying the 
effects of leucine and HMB on tumor growth. However, now that leucine and HMB have 
been shown to play roles in both muscle and pancreatic tumor growth, a pancreatic 
cancer cachexia model should be established. Most murine models of cancer cachexia 
are transplant models, where the injected cancer cells subcutaneously form tumors that 
cause weight loss from 20%-40% proportional to tumor size after 3 weeks, wasting of 
adipose and muscle tissues, hypoglycemia, hyperlacticidemia, 
hypertriacylglycerolemia, and depletion of glycogen stores (184-187). There are colon 
(MAC16 and C 26) and breast cancer (Walker 256) cells that cause cachexia, but no 
pancreatic cancer cells. To create a PDAC cell line that causes cachexia, established 
cells lines from transgenic models of spontaneous PDAC (UN-KC-6141, UN-KPC-960, 
and UN-KPC-961) could be injected subcutaneously into obese C57BL/6 mice, or 
another mouse line that is not a transgenic model of PDAC. This ensures all cachectic 
symptoms would be attributed to the injected tumor, and the obese state should 




significant weight loss would then be cultured and injected into new obese mice. If 
20%-40% weight loss occured after 3 weeks, the tumor would be excised, and if the 
weight loss is reversed, this would be a PDAC cell line that causes cachexia. Further 
analysis on adipose tissue, muscle tissue, and serum markers would have to be done 
to confirm. Tumor cells from these obese mice could be cultured and established as a 
PDAC cachectic cell line. 
 The next suggested studies would be done after characterization and proven 
repeatability of the murine cachectic model of PDAC. Due to the positive results in 
Chapter III, dietary HMB supplementation and gemcitabine treatment should be 
repeated in this model to confirm effects of HMB on tumor, muscle, and chemotherapy. 
Novel additions to this experiment could be further analysis of gastrocnemius muscle 
by measuring weight and fiber type through IHC for markers of Type I vs. Type II. 
Cachexia is known to disproportionately affect Type II (fast-twitch) muscle (188). In 
addition, the effects of HMB on local inflammatory pathways within tumor and muscle 
could be assessed through western blot analysis for the p65 subunit of NF-κB in the 
nucleus or through the visualization of NF-κB through immunofluorescence. 
Downstream analysis of various NF-κB-regulated genes could then be done to confirm. 
These experiments would help support HMB as a strong candidate for cachexia 
treatment, because they would confirm that HMB can affect these pathways in a 
cachectic model of PDAC as well as in other models of cancer cachexia. 
After the characterization of HMB in a PDAC cachexia model, additional 
mechanistic studies could be done to explore the effects of HMB on the immune 




cytotoxic CD8+ T cell infiltration into Panc02 tumors. However, there is little evidence to 
suggest why this occurred. From our study, it is evident that HMB supplementation 
increased tumor T cell infiltration at a much higher rate in the obese mice compared to 
the normo-weight mice, so it must be due to the pro-tumor obese environment. One 
aspect of this environment that can be connected to the immune system is chronic 
inflammation. Although we saw no increase in pro-inflammatory cytokine levels in the 
serum of obese mice compared to normo-weight mice, this was prior to tumor injection. 
Pancreatic cancer cells have been shown to secrete cytokines of their own and 
contribute to systemic inflammation (189). The tumors of obese mice were larger and 
could have secreted more cytokines, causing a shift towards a more inflammatory 
environment. Increased TNF-α and NF-κB activation in this environment could have 
promoted CD8+ T cell synthesis (69-70), and then HMB could have promoted T cell 
infiltration by stimulating specific pathways within the tumor. T cells normally function 
by scanning cells for major histocompatibility complex (MHC) molecules presented on 
the cell surface and destroying cells with foreign MHC molecules. Defects in the MHC 
system, such as loss or downregulation of antigen processing and antigen-presenting 
molecules, are found in various tumors and help them avoid recognition by cytotoxic 
CD8+ T cells (190). Reduction or loss of human leukocyte antigen (HLC class I) and 
transporter for antigen presentation (TAP) occurs in the majority of pancreatic cancer 
cell lines (191). HMB may be preventing the loss of HLC and TAP and subsequently 
increasing tumor cytotoxic CD8+ T cell infiltration. To determine if this is true, HMB 
should be supplemented in the diet of mice without tumors and mice with the PDAC 




tumor for HLC and TAP analysis (qPCR, western blot, IHC). This data would provide 
evidence for the mechanism behind HMB-induced cytotoxic CD8+ T cell infiltration in 
PDAC tumors. 
Similar to how adjunct treatment can strengthen a chemotherapy regimen, HMB 
could be a stronger candidate for cachexia treatment when combined with another 
treatment. One option is another popular nutritional supplement, omega-3 fatty acids, 
which are often found at high quantities in fish oil supplements. Long term omega-3 
fatty acids supplementation has been shown to enhance the anabolic (growth-
promoting) stimuli from amino acids, protein, insulin, and physical activity (192). In an 
animal model of cancer cachexia, lifelong supplementation with fish oil rich in omega-3 
fatty acids decreased tumor growth by approximately 60%, increased survival, and 
prevented weight loss. This fish oil supplementation also inhibited hypoglycemia, 
hyperlacticidemia, hypertriacylglycerolemia, and preserved glycogen stores (187). 
Previous reports also show the anti-cancer effects of omega-3 fatty acids are due to 
various mechanisms, including suppression of NF-κB, activation of AMPK and SIRT1, 
and modulation of cyclooxygenase (COX) activity (193). These studies suggest that the 
combination of long-term omega-3 fatty acid supplementation in the form of fish oil and 
short-term HMB supplementation would be beneficial both for muscle growth and tumor 
growth. This could be done in the murine model of PDAC cachexia to determine the 
effects of omega-3 fatty acids and HMB on weight loss, body composition (adipose and 
muscle mass), hypoglycemia, hyperlacticidemia, hypertriacylglycerolemia, and 
glycogen stores. Downstream effects on Akt/mTOR, NF-κB, SIRT1, and COX signaling 




the positive effects of combining HMB and fish oil (omega-3 fatty acids) on PDAC 
cachexia. 
The data presented in the current project suggests that leucine enhances 
pancreatic tumor growth, mTOR signaling, and OR expression in PDAC, while HMB 
inhibits pancreatic tumor growth, mTOR signaling, and OR expression, and increases 
cytotoxic CD8+ T cell infiltration into the tumor. Findings from the proposed studies 
would identify specific ORs involved in PDAC cell proliferation and regulated by leucine 
and HMB and characterize the effects of leucine and HMB on glycolysis and 
mitochondrial respiration within PDAC cells. Results from the proposed studies would 
also create and characterize a PDAC cachectic model that is similar to other cancer 
cachexia models, provide insight into a novel immunity-based mechanism for the 
tumor-inhibiting effects of HMB, and determine the efficiency of combination therapy 
with HMB and omega-3 fatty acids. Findings from these experiments would provide 
further insight into the varied mechanisms of cancer cachexia, leucine, and especially 
HMB, which has been administered to elderly and clinical populations safely and 
effectively for up to 12 months (194). These results could then be used in translational 
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